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ABSTRACT
The mechanism of biomineralization during endochondral ossification is an
incompletely characterized process. The small integrin-binding ligand N-linked
glycoprotein (SIBLING) group of proteins are anionic phosphoproteins found in the
extracellular matrix of mineralized tissues and have been postulated to modulate mineral
growth. Bone sialoprotein (BSP) has been shown to be a promoter of both osteoblastic
differentiation and mineralization. In contrast, osteopontin (OPN) has been shown to be
an inhibitor of mineralization. This thesis examined the phenotype of mineralization upon
loss of either BSP or OPN. When the Bsp gene was ablated in mice (Bsp-/-) histological
analyses revealed tibiae had delayed endochondral ossification, decreased mineralization,
and shortened length. Additionally, the mice had altered growth plates with decreased
chondrocyte proliferation and apoptosis, possibly contributing to the shortened bones.
Studies on Bsp-/- osteogenic cultures agreed with the in vivo findings, demonstrating
delayed osteogenic differentiation and mineralization. Adenoviral-mediated
overexpression of BSP in Bsp-/- osteogenic cultures increased osteogenic gene expression
and mineralization. Specific mutations of BSP that truncated the N-terminus, mutated
poly-E to poly-A, and RGD integrin-binding to KAE, all resulted in increased
mineralization and osteogenic gene expression. Loss of any one functional motif did not
result in loss of functionality of BSP. Deletion of Opn (Opn-/-) in murine-derived
osteogenic cultures resulted in increased mineralization with no physiological change in
osteoblast gene expression. Supplementation with milk OPN and OPN-derived peptides
reduced the enhanced mineralization of the Opn-/- osteoblasts without altering their
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terminal differentiation characteristics. These studies demonstrate that the SIBLING
proteins are potent mediators of mineralization.

KEYWORDS
Bone sialoprotein, osteopontin, hydroxyapatite, mineralization, endochondral
ossification, osteoblast, chondrocyte, development
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CHAPTER ONE

LITERATURE REVIEW

2

1.1

General introduction
Bone is a complex tissue responsible for multiple aspects of mammalian life.

Bone provides the anchor for muscles allowing them to attach and articulate movement
[1-3]. Additionally, the skeleton acts as protective case for sensitive internal organs by
shielding them from insult, and absorbing shock associated with locomotion [1, 2]. It also
acts as a reservoir for phosphate and calcium ions, which is important for metabolism,
replenishing the body when needed [1-3]. The marrow within the skeleton contains a
large progenitor cell population, from which the cells important for tissue repair,
maintenance, immune response, and homeostasis are found [1, 2]. Bone also acts as an
endocrine organ, where it can interact with the pancreas thereby modifying mammalian
metabolism [4].
Bone tissue development and mineralization is an incompletely characterized
process. This is due, in part, to the complexity of bone and the involvement of many cell
types from distinct origins that are each independently regulated yet must interact with
one another. The dysregulation of different cell types within bone results in a variety of
pathological conditions including, but not limited to: osteoporosis, osteopetrosis,
osteogenesis imperfecta, and fibrodysplasia ossifican progressiva. The mechanism by
which mineral deposition and growth is regulated is still unclear, but there are some
proteins thought to be important in the mediation of this process. The body, and its fluids
within, are supersaturated with respect to the concentration of ions required for
hydroxyapatite, the main mineral component of bone, formation and growth, but
biomineralization is restricted to discrete sites, such as bone and teeth, in normal
development. The Small Integrin-Binding N-LInked Glycoprotein (SIBLING) group of

3
proteins, discussed below, presents an ideal target to understand mineralized tissue
regulation. They are highly expressed in mineralizing tissues and have been shown to
mediate mineral growth in vitro.

1.2

Skeletogenesis
There are two mechanisms by which bone is formed during embryogenesis:

endochondral ossification, and intramembranous ossification [5-7]. The mechanism that
creates the long bones, vertebrae, and ribs, encompassing the majority of the mammalian
skeleton, is endochondral ossification [5-7]. Briefly, this process involves the
condensation of pluripotent mesenchymal progenitor cells that develop into one of two
lineages: chondrocytes or osteoblasts. The collagen of endochondral bone is regimented
in a linear pattern to provide the strength and rigidity necessary for tensile strength and
shock absorption due to movement. The second mechanism by which bone is formed is
intramembranous ossification [5-7]. This type of ossification results in the formation of
the flat bones in our bodies, such as the calvariae. Intramembranous ossification initiates
by the interaction between pluripotent mesenchymal cells and the epithelium, which
directs the mesenchymal cells to differentiate into preosteoblasts [8-10]. These
progenitors then condense, proliferate, and mature into osteoblasts that produce the
intramembranous bone, without the cartilaginous intermediate [8, 11]. The collagen
fibres of the intramembranous bone are often referred to as having a woven structure. The
fibres are overlapping in a random array of directions and do not possess an organized
pattern, such as that present in mature endochondral bone. The endochondral bones give
rise to the structures that are responsible for providing strength and rigidity in order to
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facilitate locomotion, articulation, and absorb shock. Intramembranous bone develops
structures that are mainly responsible for protecting vital organs such as the brain.
1.2.1

Primary endochondral ossification
Endochondral bone development begins as a condensation of pluripotent

mesenchymal progenitor cells, forming the primary template of bone (Figure 1.1) [12].
The condensation triggers the mesenchymal cells to differentiate into chondroprogenitors.
This is controlled by the master chondrocyte transcription factors Sox5, 6, and 9 [13, 14].
The chondroprogenitors differentiate into chondrocytes, which begin to secrete
extracellular matrix (ECM) forming the cartilaginous anlagen of the bone. The ECM
secreted by these cells is composed of type II, IX, and XI collagen, proteoglycans, and
other ECM proteins [11, 12]. The cells at the periphery of the cartilaginous anlagen begin
to flatten and elongate, forming the perichondrium [11].
At the centre of the cartilaginous anlagen the chondrocytes terminally
differentiate into hypertrophic chondrocytes [15]. As they become hypertrophic, the
chondrocytes’ expression of transcription factors Sox 5, 6, 9, and type II collagen
decrease [12, 16]. Concomitant with this reduction, there is an increase in expression of
the transcription factor Runx2, type X collagen, other ECM proteins including bone
sialoprotein (BSP), and angiogenic factors such as vascular endothelial growth factor
(VEGF) [11, 17-19]. The ECM surrounding these cells then begins to mineralize,
forming a calcified cartilaginous matrix [17, 18]. At this time, the cells in the
perichondrium differentiate into preosteoblasts, expressing osteoblastic genes such as
Runx2, alkaline phosphatase (Alp), type I collagen (Col1), among others. The ECM
secreted by these cells then begins

5

Figure 1.1 Endochondral ossification. (A) Condensation of pluripotent mesenchymal
progenitor cells (pink) of the early anlage. (B) These cells differentiate into the
chondroprogenitor cells (purple) and they begin to form the early cartilaginous anlage.
(C) The chondrocytes terminally differentiate into the hypertrophic chondrocytes (blue)
forming the early mineralized cartilaginous matrix (grey) at the centre of the anlage. The
axial chondrocytes then begin to form the growth plates at either end of the cartilaginous
anlage. The resting zone (purple) is localized at either end of the bone, and they
differentiate to form the pancake-like cells of the proliferative chondrocyte zone (teal).
Vascular invasion (red) begins in order to provide an avenue to recruit osteoclast
precursors (yellow) and resorb the mineralized cartilage matrix. (D) Primary ossification
begins as the osteoprogenitor cells (dark blue) are recruited into the resorbed areas, which
differentiate and deposit osteoid in the diaphysis. The chondrocytes localize to the
epiphysis of the bone separating the growth plates of the early bone.
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to mineralize adjacent to the hypertrophic chondrocytes. This forms the bone collar of the
developing bone [8, 17, 20].
Following the cartilaginous matrix calcifying around the hypertrophic
chondrocytes the majority of these cells begin to undergo apoptosis, leaving a porous
cartilaginous matrix in which cells can migrate to begin the modeling of the bone [21].
VEGF is secreted by the hypertrophic chondrocytes prior to apoptosis to induce
vascularisation of the cartilaginous anlage [11, 18, 22]. This provides an avenue for
osteoclast recruitment from the peripheral blood supply to the anlage [5-7].
Following the vascular invasion and degradation of the cartilaginous matrix by
chondrocyte secreted proteases and osteoclastic resorption, osteoblasts begin to secrete
osteoid. Osteoid is an ECM composed of type I collagen and a variety of non-collagenous
proteins, including BSP and osteopontin (OPN) [11]. This newly deposited matrix then
becomes calcified, forming the primary ossification centre of endochondral bone [23].
The osteoblasts that were recruited to the bone then terminally differentiate and either
become trapped in mature bone, becoming osteocytes, or undergo apoptosis [11].
1.2.2

Epiphyseal growth plate development
At either end of the developing bone chondrocytes begin to form the epiphyseal

growth plates [24]. These chondrocytes form three distinct phases of development: the
resting (reserve) zone, the proliferative zone, and the hypertrophic zone [7, 25].
Histologically these zones are distinguishable from one another based on morphology
and the expression of specific molecular markers. The resting zone consists of small
rounded cells, with low metabolic activity, which are located closest to the articular
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cartilage. The resting zone is mainly a reservoir of cells that replenish chondrocytes as
they progress into the proliferative zone as the bones develop [26, 27]. While they are
relatively quiescent cells, they still proliferate in order to replenish their numbers as they
differentiate, albeit at a much lower rate than the proliferative zone [26, 28, 29].
As the cells differentiate, they enter the proliferative zone, where the cells form
into a columnar organization of pancake-like cells surrounded by cartilaginous matrix.
These cells proliferate in a longitudinal direction towards the diaphysis; this contributes
to the lengthening of the developing bone [29, 30]. The proliferation of chondrocytes is
highly regulated by the growth factor Indian hedgehog (Ihh) [31-33]. Ihh has been shown
to enhance chondrocyte proliferation through Gli3 [34, 35]. Activation of bone
morphogenetic proteins (BMPs) have also been shown to be involved in promoting the
proliferation of chondrocytes through Smads 1 and 5 [36-39]. Following a finite number
of divisions, the cells exit the cell cycle and differentiate into prehypertrophic
chondrocytes [26]. These cells begin to lose their flat appearance and become larger than
their neighbouring proliferative cells.
The prehypertrophic chondrocytes continue to enlarge as they terminally
differentiate into the hypertrophic chondrocytes of the growth plate. The hypertrophic
zone is distinctly identifiable by the cells’ large and rounded morphology. The
hypertrophic chondrocytes grow to a size approximately five to ten-times larger than their
previous stages; this enlargement is responsible for the majority of longitudinal bone
growth from the growth plate [40, 41]. The swelling of the cells is due to increased
cytoplasm, nucleoplasm, and number of intracellular organelles [28, 42]. The matrix that
the hypertrophic chondrocytes secrete includes proteins that facilitate vascular invasion
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and the formation of the calcification of the cartilaginous matrix [28]. As endochondral
bones develop the primary centre of ossification progresses towards the epiphysis,
resulting in a progressively shrinking growth plate until the bone fully matures [5].
1.2.3

Development of secondary ossification centres
Following primary ossification and establishment of the epiphyseal growth plates,

the secondary ossification centres form. These sites begin to form in middle of the
epiphyseal cartilage of long bones [11, 43] through a mechanism that differs from
primary ossification. Secondary ossification begins with vascular invasion of the nonmineralized cartilage of the epiphysis [43], followed by hypertrophic chondrocyte
mediated calcification [11, 44, 45]. The vascularisation allows recruitment of the
osteoclasts that proceed to resorb the mineralized cartilaginous matrix. Following the
resorption, osteoprogenitor cells are recruited and differentiate into osteoblasts that
deposit the osteoid which mineralizes within the growth plate forming mature secondary
ossification centres [45, 46]. The cartilage that is adjacent to the joints becomes the
articular cartilage of mature bone. The secondary ossification front begins to grow
towards the primary ossification centre. In humans, but not rodents, this results in the
eventual replacement of the growth plate with bone [29, 47].
1.2.4

Bone modeling, remodeling, and repair
Bone modeling and remodeling are processes whereby bone is resorbed and

replaced in order to form the mature tissue and to maintain its structural integrity (Figure
1.2). The resorption of bone is performed by osteoclasts, a multinucleated cell type
derived from a mononuclear haematopoietic myeloid cell lineage that becomes the
mononuclear osteoclast precursors that fuse to form multinucleated cells. These cells
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Figure 1.2 Cellular involvement during bone remodeling. Osteoclast precursors are
recruited to sites of mature bone to initiate bone resorption. Osteoclast precursor cells
begin to merge, forming large multinucleated cells that differentiate into osteoclasts.
When osteoclasts are actively resorbing they develop a ruffled membrane at the bone
surface, and they secrete proteases and acidify matrix forming the resorptive pits. The
mesenchymal progenitors are then recruited and differentiate into the preosteoblasts. As
they move into the resorptive pits they differentiate into osteoblasts. The osteoblasts
deposit de novo osteoid that integrates with the neighbouring bone and mineralizes.
Osteoblasts then undergo one of three final stages: apoptosis, differentiation into bone
lining cells, integration into bone by becoming osteocytes.
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are large, around 150-200 µm, and have a large number of vesicles in the cytoplasm. As a
pre-requisite for resorption the osteoclast forms a tight seal with the bone surface. The
osteoclasts then develop a highly folded membrane, the ruffled border, in order to
increase the surface area to maximize secretion and uptake activity. These cells are also
identifiable by their expression of tartrate-resistant acid phosphatase (TRAP) and other
cell surface markers such as receptor activator of nuclear factor-κB (RANK). Due to the
constant stresses on the structure of bone, remodeling is crucial in maintaining its
integrity. Both modeling and remodeling is begun by the recruitment of osteoclast
precursor cells to the sites of resorption by the osteoblastic and stromal cell secretion of
RANK ligand (RANKL) and macrophage colony stimulating factor (MCSF) [48].
RANKL promotes the proliferation of the osteoclast precursors at the site of resorption.
Following the proliferation, MCSF promotes their aggregation to form the functional
osteoclasts. The fusion of the monocytes results in a multinucleated cell that typically
consists of 6-14 nuclei. The osteoclasts begin to resorb the mineralized matrix using
proton pumps to acidify and dissolve the mineral in the area to be degraded. Following
dissolution of the mineral, the decalcified collagenous matrix is then proteolytically
degraded by cathepsins [49]. Osteoprogenitors are then recruited to sites of resorption
where they differentiate into osteoblasts and secrete de novo osteoid. The new osteoid
seamlessly integrates into the stable bone tissue. The new osteoid then mineralizes,
resulting in a fully repaired bone that restores the strength of the tissue.
Following traumatic injury such as a bone fracture, a similar mechanism is
activated in order to repair the damaged tissue. In these cases the insult normally results
in the release of blood into the region surrounding the break [50, 51]. The blood comes
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into contact with bone, resulting in enzymatic release of chemotactic molecules into the
area surrounding the site of injury that promote cell recruitment to initiate the repair and
remodeling process. The first step in bone repair is the formation of a bone callus. This
callus is formed in a mechanism that closely resembles endochondral ossification where
first a cartilaginous matrix is formed. The chondrocytes within this cartilage then undergo
terminal differentiation into hypertrophic chondrocytes and begin to promote vascular
invasion. This, as during endochondral ossification, initiates the recruitment of osteoclast
progenitor cells to resorb the tissue. The newly resorbed areas are then filled with de novo
osteoid by osteoblasts, forming the repaired bone matrix. This results in the repair of the
tissue, but does not necessarily result in a perfectly integrated mineralized matrix with the
same shape and/or flexibility as the native, uninjured bone.
1.2.5

Clinical pathologies of bone
Impairment of development at various stages of bone development can result in a

wide array of defects. An uncoupling of cell proliferation and terminal differentiation can
result in changes that lead to a variety of skeletal dysplasias. These defects often lead to
dwarfism and shortening of the appendicular skeleton and/or the axial skeleton [52, 53].
Defects in chondrocyte development, chondrodysplasias, can be caused by: mutations in
FGFR3 receptors, resulting in achondroplasia [54]; mutations in SOX9, resulting in
campomelic dysplasia [55, 56]; type II collagen mutations leading to type II
collagenopathies [5, 57, 58]; type IX collagen mutations leading to epiphyseal dysplasia
[5]; and type X collagen mutations leading to Schmid metaphyseal chondrodysplasia [5].
These defects in chondrogenesis account for only a small number of all skeletal
dysplasias [5, 59].
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Other bone defects include the decoupling of bone deposition and resorption. One
such defect, osteoporosis, is caused by the increased resorption by the osteoclasts and
decreased deposition by the osteoblasts, resulting in decreased bone mass [60]. The
corollary of this is the increased matrix deposition and decreased resorption, resulting in
osteopetrosis [61]. Interestingly, both of these diseases result in brittle bones that are
more prone to fracture. Osteoporosis alone affects 33% of women and 20% of men. This
translates to over $2.3 billion in health care costs in Canada (as of 2010) [62]. Another
prevalent pathology of bone, affecting 30-50% of individuals within the United States, is
periodontal disease [63-65]. This disease presents as alveolar bone degradation that leads
to tooth detachment and loss. Understanding the mechanism of bone development will
provide targets for the development of therapeutics to promote the regeneration of bone
tissue. This thesis addresses the roles of two proteins during bone development that could
be clinically relevant in the regeneration of bone.
1.3

Osteoblasts
Osteoblasts are a cell type derived from a similar mesenchymal progenitor to the

chondrocytes [66]. Histologically, the osteoblasts are more difficult to observe as they
develop than chondrocytes. A cell culture analysis of osteoblasts provides a method to
examine the characteristics of osteoblast differentiation and mineralization [67].
Osteoblastic differentiation is controlled by the master osteogenic regulators Runx2 and
Sp7 [68]. As they mature from an osteoprogenitor cell and become osteoblasts, they
begin to secrete osteoid, and express osteocalcin and BSP [69]. When the osteoblasts
terminally differentiate, they undergo one of three potential pathways of terminal
differentiation [67]. First, should the osteoblasts become trapped within matrix of bone,
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they develop into osteocytes. The osteocytes are a crucial regulatory cell secreting
signaling molecules in order to maintain bone homeostasis. Second, the osteoblasts may
also differentiate into periosteal bone lining cells. These cells are, for the most part, inert
and await activation from endocrine signaling molecules. Thirdly, the osteoblasts may
also undergo apoptosis.
1.3.1

Osteoblast cell culture
The study of osteoblasts in vitro cell cultures systems has been performed using a

number of techniques (reviewed in [67]). Osteoblasts can either be primary, such as those
isolated from the mesenchymal stromal population or from neonatal calvaria, or they can
be a cell line, commonly MC-3T3-E1 or ROS17/2.8 cells. In all cases, the cells are grown
in a two-dimensional culture system that is supplemented with ascorbate and glycerol-2phosphate (G2P). Ascorbate acts as both a signaling molecule to promote osteogenic
development, and as a molecule that is required for collagen synthesis. G2P is an
important source of organic phosphate that when cleaved by alkaline phosphatase is
incorporated into the mineral. These cells are capable of surviving for long periods of
culture at a high density, permitting time-course experiments to characterize changes in
gene expression and mineralization. The culture of osteogenic cells allows study of
specific roles of individual factors related to osteoblastic differentiation and
biomineralization.
1.4

Biomineralization
Biomineralization is a complex process by which dissolved salts are precipitated

to form highly ordered mineral crystals of hard tissues in living organisms. This is an
extremely desirable process as it provides both structure and protection. Undesired
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biomineralization results in a number of clinical pathologies covered in Sections 1.2.5
and 1.5.2.3. As such, it has been conserved through all five animal kingdoms, and has
been a common feature of animal tissues for approximately 3.5 billion years [70]. The
development of the mineralized skeleton occurred at some point during the Cambrian
explosion [70]. The primary biominerals that are produced by a variety of organisms
include: calcium carbonate for external skeletal carapaces of invertebrates, and
hydroxyapatite for the internal skeletal structures of mammals [70]. Highly acidic
proteins, such as those in the SIBLING family, have long been thought to be a
determinant of biomineral growth [71]. Animals, such as sharks, that have nonmineralized cartilaginous skeletons do not have the SIBLING family of genes supporting
their role in directing biomineralization [72].
The rigidity of the mammalian skeleton is due to the carefully regulated
deposition of a calcium phosphate mineral, primarily hydroxyapatite (HA), within the
collagen lattice. The mineral within the collagen matrix provides the strength for bone to
withstand the constant stresses applied to it, while the collagen provides torsional
strength to alleviate the brittleness of mineral. Furthermore, citrate has recently been
implicated to play an important role in absorbing shock and preventing the aggregation of
the HA crystals [73]. The amount of mineral deposited within bone is a process that
requires careful balance. Too much mineral results in a brittle tissue; too little mineral
and the tissue cannot withstand the stresses applied to it. Interestingly, the localization of
mineral is restricted to specific sites within the body, under normal conditions.
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1.4.1

Hydroxyapatite
The mineralized portion of mammalian bones is composed primarily of HA

[Ca10(PO4)6OH2]. HA is a stable precipitate of calcium and phosphate. Its precipitation is
thought to be regulated by extracellular matrix proteins, as collagen alone has been
shown to be unable to promote mineralization [74-77]. HA has a very ordered structure
that provides the necessary stability to bone. It propagates longitudinally alongside the
collagen fibres in vivo. The typical dimensions of HA are 45x25x5 nm [78-80] with the
longest face parallel to the collagen. The mineral crystals are tightly packed within the
collagen fibres to provide the characteristic rigidity of bone.
1.4.2

Collagen
While the mineral is the key to bone’s rigidity, the organic matrix is the

component responsible for its flexibility and stabilizing articular movement. This organic
matrix, the osteoid, is composed mainly of type I collagen, although there is a mixture of
many non-collagenous proteins, including the SIBLING proteins. The type I collagen
provides the basic scaffold of bone, while the other non-collagenous proteins are
incorporated with the collagen in order to modulate crystal growth, orientation, and cell
recruitment [81].
The main organic component, approximately 90%, of bone is collagen. Of the
currently known 28 types of collagen that have been described, bone is composed
primarily of type I collagen. Coexpressed with type I collagen in bone are the
quantitatively minor collagen types V[82], XI [83], and XXIV [84]. These collagens are
thought to be important for controlling the collagen fibril diameter [82, 83] which
modulates the fibril strength. As previously mentioned, mineral is required to provide the
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rigidity, while collagen is necessary for providing tensile strength. The unique structure
of collagen provides properties that are singular in its ability to retain structural integrity
and resist denaturation [85].
Type I collagen is a triple-helical molecule formed from two α1 and one α2 chain
[86-88]. Both of these chains form a left-handed helix, and when they associate with each
other wind into the right-handed conformation of the triple-helix of complete collagen.
Each of these polypeptides is of a length of approximately 1000 amino acid residues.
When combined, the mass of the triple helical chains is approximately 300 kDa. The
specific chains are formed from a repeating pattern of amino acids of (Gly-X-Y)n.
Frequently, X is proline, while Y is 4-hydroxyproline. This allows the hydrogen of the
side chain of Gly to be centred within the helical structure and permits the –OH groups
on the 4-hydroxyproline to form hydrogen bonds, providing stability to the molecule [8991].
The triple-helical type I collagen molecules interacts with other type I collagen
molecules to form aggregates that are called collagen fibrils. These collagen fibrils
assemble in an overlapping pattern such that there are empty regions between each triple
helical collagen molecule termed the hole zones. This is what is termed the staggered
array of collagen shown in Figure 1.5 [92]. It is in the 67 nm-long hole zones of this array
that mineralization is thought to initiate [78, 80, 93-96].
1.4.3

Theoretical models of biomineralization
The process of mineral deposition in bone is an incompletely characterized

process that appears to be mediated by a number of highly controlled mechanisms. The
body is in a constant state of supersaturation with respect to calcium and phosphate for
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HA nucleation [97]. Despite this, the body tends to have no ectopic calcifications. This
includes locations of higher levels of ion concentration, such as milk and blood. In order
to regulate the process of biomineralization, there is likely an intricate interplay between
the proteins and ions within the body. Biomineralization is thought to begin in the
aforementioned hole zones within the collagen lattice [94, 95, 98]. This has been
demonstrated to be the case in turkey tendon by Arsenault et al [94] and later in human
bone [78]. They showed that following the initial nucleation of mineral within the hole
zones, the HA crystals then propagate longitudinally parallel to the C-axis of the collagen
lattice [99].
The nucleation of mineral is thought to be initiated through one of a few different
models. One model proposes that nucleation of mineral is initiated by the acidic
regulatory proteins that are localized within these hole zones [78]. It is hypothesized that
these highly acidic non-collagenous regulatory proteins bind calcium in order to
ultimately form the critical nucleus of HA either through heterogeneous or epitactic
nucleation, discussed below. Another model that has been proposed suggests that the
biological inhibitors, such as OPN and pyrophosphate, are removed in order to permit the
mineral to grow.
Heterogeneous nucleation is a process by which mineral grows on a non-mineral
surface [100]. In the case of mammalian skeletons, this is a matrix-mediated system
where osteoid is the surface on which the critical nuclei are formed. The surface
chemistry of the matrix is required to be capable of sequestration and/or deposition of
ions onto the scaffold, or stabilization of the sub-critical nucleus resulting in the crystal
growth [101]. One mechanism by which matrix-mediated growth is thought to occur is by
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sequestering ions to the surface of the matrix [102]. Following sequestration, the ions are
condensed into nano-particles, eventually leading to the formation of a critical nucleus
that grows to mineralize the organic matrix.
Epitactic nucleation is a form of crystal nucleation where a surface, provided by
an organic system, acts as a mimic of a crystal face [100]. This has been demonstrated in
the nacreous layer of a mollusk shell, where it is capable of providing a surface that
mimics a crystal face to promote biomineralization [103]. Many of the proteins thought to
be involved in the binding and/or nucleation of crystals are inherently acidic, or contain a
number of phosphates to provide the negative charge. This is the mechanism by which
BSP is thought to act in order to promote biomineralization [104, 105].
1.4.4

Inhibition of mineralization
Within the process of biomineralization, there is a complex interplay between the

growth and inhibition of mineral. Inhibition is required in order to regulate the overall
speed and the amount of crystal that is formed in hard tissues. Inhibition of growth is also
desirable to prevent or slow pathological calcification of soft tissues, such as
atherosclerosis and kidney stone formation. Molecules that have been shown to be
strongly correlated with the inhibition of mineral growth are OPN [106-108], matrix-gla
protein [109], and pyrophosphate [110]. These regulators of growth can act on mineral in
a couple of different ways [111]. The first is during the initial precipitation of calcium
phosphate nanoparticles whereby these inhibitors bind and block further particle growth.
The second is when these molecules bind the surface of growing mineral crystals to
competitively inhibit further ion deposition. These mechanisms result in the retardation
of the growth of mineral crystals.

21

1.5

General introduction to the SIBLINGs
The Small Integrin-Binding LIgand N-linked Glycroprotein (SIBLING) family is

a group of proteins that includes bone sialoprotein, osteopontin, dentin matrix
phosphoprotein (DMP1), dentin sialophosphoprotein (DSPP), which is cleaved into
dentin sialoprotein (DSP) and dentin phosphophoryn (DPP), and matrix extracellular
phosphoglycoprotein (MEPE). All of these proteins are derived from a common ancestor
that is shared with other calcium-binding proteins found in enamel, milk, and saliva
[112]. The genes encoding members of the SIBLING family are located in a syntenic
gene locus that has been named the “bone gene cluster” located on murine chromosome 5
[113], and human chromosome 4 (4q21) depicted in Figure 1.3 [112]. Genetically, these
proteins are localized as single copy genes with similar intron-exon patterns [112]. For
example, the first exon is non-coding, the second exon contains the loader sequence and
first amino acids of the protein, with one of the final exons containing the RGD integrinbinding sequence. SIBLING proteins are thought to be a crucial regulatory element of
biomineralization in animals. Animals with cartilaginous skeletons, such as sharks, lack
these genes, and as such lack a mineralized skeleton [72].
These proteins all share similar features in regards to their structure and function.
All the members of this family are intrinsically disordered proteins, thus they have a
flexible structure [81, 114-118]. This flexibility is thought to be important in their ability
to bind multiple motifs while maintaining their function in situ. All of these molecules
are highly acidic and may also contain contiguous acidic amino acid residues, either
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Figure 1.3: Schematic of human chromosome 4 with the locations of the SIBLING
genes. The SIBLING genes are located between site 4q21 and 4q23. Each gene encodes a
single copy gene. The SIBLING family and all they share similar intron-exon patterns,
structural, and functional characteristics.
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glutamic acid or aspartic acid [114, 119-122]. This electronegativity is responsible for
binding to the mineral with which they interact. These proteins also contain extensive
post-translational modifications, including phosphorylation, glycosylation and sulfation.
Phosphorylations have been identified to be a modification that alters the ability to
nucleate [123], inhibit, and bind [124] mineral. Finally, all these proteins contain an RGD
sequence that binds cell-surface integrins in order to promote cell signaling.
1.5.1

Bone sialoprotein
Bone sialoprotein was first identified as one of the most abundant non-

collagenous proteins in bone. BSP was originally isolated as a 23 kDa fragment from
bovine cortical bone in the 1960s [120, 125, 126]. Comprehensive characterization of the
molecule was not completed until nearly two decades later, when the rat BSP cDNA
sequence was elucidated in 1988 [127]. The complete characterization of BSP identified
it as an anionic phosphoglycoprotein with a high concentration of sialic acid residues and
extensive post-translational modifications [128, 129]. BSP is calculated to have a
theoretical molecular mass of 33-34 kDa [120], but following post-translational
modification, it tends to run between 60 and 80 kDa on a sodium dodecyl sulfatepolyacrylamide gel (SDS-PAGE) [130]. BSP is highly conserved in all species with
mineralized skeletons. This includes a wide variety of animals including chicken, frogs,
and mammals [131, 132]. BSP’s redundancy and conservation is an indication of its
importance in the regulation of biomineralization and bone development. BSP’s anionic
characteristics and its prevalence in mineralized tissues suggest that it is one of the
primary regulators of biomineralization in bone and teeth. Experiments performed
following its primary sequence characterization by Oldberg et al. [127] have
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demonstrated that BSP is a potent nucleator of mineralization [105], and it has a strong
propensity to bind hydroxyapatite mineral, discussed below.
1.5.1.1 Structure and functional regions
BSP is an intrinsically disordered proteins with little or no secondary or tertiary
structure [81, 133, 134]. It contains highly conserved poly-glutamate sequences [131,
132] that are critical for hydroxyapatite (HA) nucleation [105] and binding [128, 135].
BSP contains an amino-terminal collagen-binding sequence, a carboxy-terminal integrinbinding RGD sequence, and two central highly acidic poly-glutamate sequences [120]. A
schematic of BSP and its functional regions are shown in Figure 1.4. The collagenbinding sequence mediates the attachment of BSP through hydrophobic interactions
[136]. When bound, BSP has been demonstrated to have enhanced nucleation potency
[137]. The RGD sequence of BSP mediates cell attachment [138, 139], but it also has
been demonstrated to promote osteoblast cell differentiation and mineralization in vitro
[140, 141]. BSP acts through binding the cell-surface integrins αVβ1 [142], αVβ3 [143],
and αVβ5 [144]. Due to the expression characteristics of BSP and its functional regions, it
is postulated to be a potent initiator of biomineralization and mineralized tissue
development in vivo.
Cell types involved in bone homeostasis, osteoblasts and osteoclasts, have both
been demonstrated to be controlled by BSP-mediated cell-surface receptor activation and
intracellular signaling. Overexpression of BSP in MC3T3-E1 osteogenic cells promotes
terminal differentiation through the cellular signaling pathway involving focal adhesion
kinase and extracellular signal-regulated kinases [140]. This results in an increase in
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Figure 1.4 Linear schematic of bone sialoprotein. BSP is approximately 300 amino
acids long. The collagen-binding sequence (yellow) is localized at the N-terminus. There
are two poly-glutamate sequences (red) that are responsible for binding and nucleation of
HA. There is also a C-terminal RGD integrin-binding sequence (blue) that promotes cell
adhesion and signaling.
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expression of osteoblastic markers such as Runx2, Sp7, and Bglap in MC3T3-E1 cells
[141]. In addition, the osteoblasts demonstrate an increase in matrix mineralization,
compared to the control, when supplemented with recombinant BSP, or when BSP is
overexpressed. Conversely, treating MC3T3-E1 osteoblastic cells with shRNA, to reduce
BSP expression, results in a decrease of matrix mineralization and osteoblast marker
expression. These studies show that BSP is a promoter of differentiation and
mineralization of osteoblasts in vitro.
Osteoclasts have also been demonstrated to both express BSP [145] and interact
with it [146, 147]. The osteoclastic interaction with BSP appears to be dependent on the
phosphorylation state of BSP, as loss of phosphates results in osteoclasts less able to
adhere as compared with phosphorylated BSP [148]. Phosphorylation of BSP promotes
osteoclastic resorption in vitro [149]. BSP also mediates both the influx [150-152] and
the efflux [153] of Ca2+ from the osteoclasts, suggesting that it may be involved in
intracellular signaling. BSP appears to be most important, but not critical, in directing
osteoclastogenesis [154, 155] and bone resorption [156], as further discussed below
(Chapter 1.5.1.4). Due to BSP being an active regulator of both osteoclasts and
osteoblasts, BSP is thought to have an important role in mediating the homeostasis of
bone in vivo.
1.5.1.2 Expression and regulation
Under normal physiological conditions, BSP is expressed by mineralizing cells
such as hypertrophic chondrocytes, osteoblasts, cementoblasts, ameloblasts, and
odontoblasts [145, 157, 158]. In bone its expression is mainly restricted to sites of de
novo bone formation [157, 159]. The only non-mineralized cells that have been shown to
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express BSP natively are the trophoblasts during early embryonic development [145] and
salivary glands [160]. The expression by trophoblasts is thought to be important for
directing cell migration, as well as promoting the implantation of the embryo in utero.
Previous studies investigating the temporospatial expression characteristics of BSP in de
novo bone formation have demonstrated that it is expressed by hypertrophic chondrocytes
and osteoblasts at a time coinciding with the onset of mineralization [145, 157, 158, 161].
However, BSP expression patterns in developing chondrocytes of the growth plate are
still controversial [145, 157]. BSP is also expressed at high levels in other mineralized
tissues, including cementum, and dentin [120]. BSP is detectable in the Golgi apparatus
of osteoblasts, as it is post-translationally modified and prepared for secretion
[161].These investigations of the expression of BSP suggests that it may be an important
regulator of biomineralization as well as cell growth and migration characteristics.
Transcriptional expression of BSP is regulated by a number of different
molecules. Basal expression levels are provided by a TATA-like box (TTTATA) and an
inverted CCAAT box (GGTTA) [162, 163]. Additionally, transcription factors that have
been shown to bind to the promoter sequence include: Ap-1, Cre, and NF-κB [162-164].
Runx2 has also been shown to be a promoter of Bsp transcription in osteogenic [140,
141] and non-osteogenic cells [165]. BMPs are a class of molecules that promote both
BSP expression and osteogenic differentiation [166]. Due to BSP’s role as a promoter of
biomineralization, its expression is normally silenced. These complex regulatory
characteristics are crucial to the maintenance of homeostasis and restricting mineral
deposition to desirable areas.
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1.5.1.3 BSP-mediated nucleation
BSP has been shown to a potent nucleator of hydroxyapatite crystals [105]. This
is hypothesized to be initiated through a mechanism where the highly acidic sequences
attract Ca2+, which in turn recruits PO4- (Figure 1.5). Eventually this collection of ions
forms a critical nucleus, which leads to the collagen being mineralized. The attached
phosphates are thought to be an important element regulating the nucleation potency of
BSP, and one in particular, serine-136, has been identified to be promote BSP’s
nucleation potency [167]. The binding of BSP to collagen also enhances the ability for
BSP to nucleate mineral in a steady state collagen-gel system [137].
1.5.1.4 Transgenic BSP mice
Genetic manipulation of the expression of BSP in vivo has resulted in some
interesting phenotypes. First, overexpression of BSP cDNA in mice by the
cytomegalovirus (CMV) promoter (CMV-BSP) resulted in shortened bones and increased
mineralization [155]. The changes in the growth plate described by Valverde et al.
showed a decrease of the proliferative zone in the tibia of the CMV-BSP mouse [155].
This decrease of proliferative zone length due to over-expressing BSP is likely due to
BSP promoting early cell-cycle exit due to terminal differentiation. This is evidenced by
the CMV-BSP mouse demonstrating increased numbers of hypertrophic chondrocytes.
Additionally, these mice demonstrate an uncoupling of bone deposition and resorption.
The bones of CMV-BSP mice have fewer differentiated osteoblasts and either increased
activity or greater numbers of osteoclasts.
Interestingly, ablation of Bsp in a transgenic mouse model (Bsp-/-) results in mice that are
phenotypically similar to the CMV-BSP animals. These mice also have shortened long
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Figure 1.5 BSP-mediated nucleation in the hole zones of the collagen scaffold. (A)
Schematic of the staggered array of collagen fibrils with BSP (yellow and red) bound to
collagen either adjacent or within the hole zone. The negative charge of BSP promotes
the recruitment of the ions to form the critical nucleus. (B) BSP is postulated to stabilize
the formation of the critical nucleus within the hole zone of the collagen scaffold,
promoting the growth of the calcium phosphate crystals to form HA and mineralize the
bone.
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bones and increased trabecular bone density at 4-months-of-age compared to their wildtype controls [154]. These phenotypes are likely caused by differing mechanisms. The
increased bone density is proposed to be the result of the mice lacking the same bone
turnover rate as the wild- type mice. In contrast to this, the Bsp-/- mice have been
demonstrated to have decreased mineralization of cortical bone and a significant delay in
cortical bone repair following injury [168]. This process of repair in many ways mirrors
bone development and this suggests a defect in endochondral bone development,
although direct investigation of the developing bone is yet to be performed. What is
known of the defect during development is that there is a minor decrease in
mineralization of bone in Bsp-/- neonatal mice [154].
As mentioned above, in vitro studies have shown that BSP interacts with
osteoclasts, thereby promoting the attachment and mineralized-surface resorption activity
[156, 169]. However, Wade-Gueye et al. demonstrated that ovariectomized Bsp-/- mice
are still susceptible to significant bone loss or osteoporosis, suggesting that BSP is not a
critical requirement for osteoclast attachment and bone resorption in vivo [170]. Previous
work investigating BSP’s potential to promote repair of bone defects supports this
hypothesis, as BSP has been shown to positively enhance mineralization and repair in
vivo [171].
In addition to these defects in bone mineralization, BSP is also involved in
cementum formation and is integral to proper tooth attachment [172]. Loss of BSP in this
model also resulted in significant tooth resorption and alveolar bone degradation. These
studies suggest that BSP is also an important regulatory element in the development and
mineralization of periodontal tissues in vivo.
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1.5.2

Osteopontin
Osteopontin is an anionic phosphoprotein that is present in many tissues and cell

types, including bone and physiological fluids [173]. OPN is also expressed during
inflammation, wound healing, and pathological conditions such as cancer [174],
discussed below. As such, it was concurrently characterized by a number of independent
investigators studying a variety of different tissues. It was first isolated and identified as a
60 kDa transformation-associated phosphoprotein [175]. It was also identified as a 57
kDa molecule that is present in the calcified matrix of bone [176-178]. Shortly thereafter,
the primary sequence of OPN was characterized by molecular cloning and sequencing
from rat cDNA [119]. OPN is calculated to have a theoretical molecular mass of 33-34
kDa [173, 179], but similarly to BSP, it runs slower at 44 to 75 kDa, by SDS-PAGE. This
is likely due to the strong anionic charge as well as extensive post-translational
modifications, including phosphorylations, that result anomalous sizes as determined by
SDS-PAGE [173, 179]. OPN has been shown to be a potent inhibitor of the formation
and growth of calcium oxalate [180] and calcium phosphate in vitro [106, 124].
When OPN was first identified, it was given a number of names that reflect the
different tissues from which it was characterized. These include early T-lymphocyte
activation, secreted phosphoprotein, uropontin, and bone sialoprotein I. The name bone
sialoprotein I was due to it having a high sialic acid content, while the protein currently
known as BSP was called BSP-II [177]. The eventual name change to osteopontin, from
BSP-I, is derived from its ability to provide a bridge (pons) between the cellular phase
and mineral phase (osteo).
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1.5.2.1 Structure and functional regions
As mentioned previously, OPN shares a number of functional characteristics with
the other members of the SIBLING family. A schematic of OPN is presented in Figure
1.6. First, it is intrinsically disordered and shares the flexible structure of the other family
members [181]. It also contains regions of contiguous acidic residues, in this case polyaspartate, required for mineral binding and inhibition [135, 182]. Like BSP, OPN has
been shown to be capable of binding collagen [183]. OPN also contains a “QKQ”
transglutaminase cross-linking site, important for the formation of polymers with other
OPN molecules and other proteins [173]. When isolated from bone, OPN has been shown
to be highly cross-linked [184], in contrast with other SIBLING proteins. This
polymerization is thought to be important for enhancing OPN’s ability to bind collagen
[185]. Additionally, OPN contains cell signaling sequences including the SIBLINGshared RGD sequence [173, 179], multiple CD-44 binding sites [186-189], and a cryptic
murine SLAYGLR sequence [190] that is exposed upon thrombin cleavage [191].
Phosphorylation of OPN has been demonstrated to be one of the major mediators
of its functions [179]. Varying the number of phosphorylations has been suggested to
change its interactions based on cell type. For instance, MDA-MD-435 cancer cells more
readily adhered to OPN derived from fibroblasts (low phosphorylation) than osteoblastderived OPN (high phosphorylation) [192]. In contrast, this study also demonstrated that
the mouse ras-transformed 275-3-2 embryonic fibroblasts preferably adhered to the
osteoblast-derived OPN than the fibroblast-derived OPN. Furthermore, it has been shown
that macrophage recognition of OPN is dependent on its phosphorylation state [189]. Its
phosphorylation state is also known to promote the adhesion and spreading of
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Figure 1.6 Linear schematic of osteopontin. OPN is approximately 300 amino acids
long. The poly-aspartic acid sequence (green) is responsible for binding and inhibition of
mineral growth. There is also a central RGD integrin-binding sequence (dark blue) that
promotes cell adhesion and signaling, as well as a cryptic SLAYGLR sequence that is
activated upon thrombin cleavage
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macrophages, and their migration is augmented upon OPN treatment [189]. It has also
been demonstrated that osteoclast activity is dependent on OPN post-translational
modification [149]. Thus, the response to the phosphorylation state of OPN is cell-type
specific.
1.5.2.2 Expression and regulation
The expression patterns of OPN in normal physiological conditions are highly
complex and dependent on a variety of regulatory elements. Opn is transcribed from a
single copy gene. It can be spliced forming multiple versions of the protein [193, 194],
but its primary expression tends to be full-length OPN. In bone, expression of OPN has
been shown to be linked with formation of new bone along the mineralizing front [195].
This high expression level suggests that OPN may regulate the growth of the mineral
crystals being deposited during de novo bone formation. The expression of OPN in
osteoblasts is dependent on a variety of regulatory factors, including: synthetic
bisphosphonates [196], inorganic phosphate [197], and 1,25-dihydroxyvitamin D3 [196,
198]. In addition, studies have suggested that OPN expression is regulated by Ank and
PC-1 (gene name Enpp1) in relation to osteoblasts exposure to inorganic phosphate in the
cell culture medium [199-201].
The role of OPN expression in osteoblasts presents a controversial story. OPN is a
marker of osteoblast development, and its role during osteoblast development is still not
fully characterized. The integrin-binding RGD sequence in OPN is predicted to play a
role in promoting osteoblast signaling [202, 203], and has been shown to both promote
[204] and inhibit [205] osteoblast differentiation. This, in turn, resulted in increased and
decreased mineralization in their studies, respectively. Clarification of the effects of OPN
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on osteoblast development will help to elucidate the role of this protein in the regulation
of biomineralization.
1.5.2.3 Inhibition of mineralization
OPN has been shown to be a potent inhibitor of HA nucleation and growth in
vitro [106, 124]. OPN has been studied extensively in order to understand the role it plays
in regulating crystal growth. It has long been known that OPN is involved in a variety of
pathological conditions including: atherosclerosis [206], and kidney stones [207]. The
first motif of OPN shown to inhibit mineralization is that of the highly acidic polyaspartate regions [124, 208]. Other binding motifs that do not contain poly-aspartate have
also been shown to inhibit crystal growth, as reviewed by Azzopardi et al. [209]. These
sequences generally include sites with phosphorylations imparting a greater
electronegativity. These crystal binding regions of OPN competitively perturb mineral
growth by interacting with the positively-charged calcium molecules of the crystal
surfaces [210]. Bovine milk OPN has been shown to directly inhibit HA nucleation by
binding crystal faces of HA using its multiple crystal-binding motifs [210-212].
There are a number of reports in the literature of OPN being associated with
atherosclerotic plaques [206, 213-217], which has lead to experiments investigating its
role in cell cultures of vascular smooth muscle cells (VSMCs). OPN is thought to play a
role inhibiting mineralization in these cells due to its localization within atherosclerotic
plaques [206, 218]. Supplementation of the VSMCs with exogenous OPN isolated from
neonatal rat smooth muscle cell cultures resulted in decreased mineral deposition [219].
In a similar system, Opn-/- cells were grown under high phosphate conditions to induce
calcification, and were shown to have increased mineral deposition relative to WT
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controls [220]. These studies suggest OPN inhibits pathological calcifications in
atherosclerotic plaques.
Of the aforementioned motifs responsible for crystal growth inhibition, two OPN
sequences have been studied in detail to understand their ability to adsorb to mineral and
inhibit its growth in vitro [209]. The inhibiting peptides that had high electronegative
charge were shown to be capable of strongly binding to HA crystal faces, while more
neutral peptides resulted in no crystal growth inhibition. These studies suggested that the
negatively charges regions, due to phosphorylation or the contiguous poly-D sequence of
OPN, are critical attributes for mineral crystal binding and inhibition.
1.5.2.4 Opn-/- mice
Mice with the Opn gene ablated (Opn-/-) have been reported to have a number of
phenotypic anomalies that are not readily apparent unless challenged or probed carefully.
They have increased bone mineral density when assayed using Fourier transform infrared
(FTIR) imaging [221]. This phenotype develops progressively as the animals age,
suggesting a dysregulation between mineral deposition and resorption [221]. Rittling et
al. have demonstrated that Opn-/- mice have reduced osteoclast activity [222], suggesting
that their increased mineral density phenotype is caused by impaired mineral resorption.
Moreover, the mice show many atypical responses to stress. Reduction of the mechanical
stress, via tail-suspension unloading, resulted in a lack of osteoclastic response. Without
OPN, mechanical signaling is impaired and there is no increase in the resorptive capacity
compared with wild-type controls. There is further data to suggest that the Opn-/- cells
isolated from spleen and bone marrow readily form osteoclasts. This suggests that OPN is
required for osteoclast resorption, while it is not involved in osteoclast formation remains
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unchanged [223]. This hypothesis is further supported by the fact that when the Opn-/mice are implanted with bone discs, only those discs treated with OPN are resorbed
[224]. This could be due to the inability for cells to localize to sites of resorption and/or a
decreased capability for the osteoclasts to act, thus impairing their ability to resorb the
bone. These data propose that OPN is an important regulatory element responsible for
translating mechanical effects to the cells involved in bone homeostasis.
1.5.3

Disorders associated with SIBLING proteins
The majority of abnormalities that arise within mineralized tissues are associated

with the expression and mutations of the collagen genes, and none have been attributed to
aberrations of the SIBLING proteins so far. Interestingly, oral pathologies have been
shown to be caused by mutations within the chromosomal region containing the
SIBLING proteins in humans [225]. These oral pathologies include dentinogenesis
imperfecta and dentin dysplasia [225-227]. These defects in humans are similar to the
phenotypes of mice with the deletion of Dspp [228] and Dmp1 [229]. The Dspp-/- mice
demonstrate a phenotype of widened predentin, a defect in mineralization that is similar
in phenotype to dentinogenesis imperfecta type II. The phenotype of the Dmp1-/- mice
includes a number of defects during postnatal tooth development that also match
dentinogenesis imperfecta in humans. As mentioned above, the loss of BSP also resulted
in the loss of acellular cementum in mice [172]. These studies suggest that the SIBLING
proteins are integral to normal odontogenesis, and that aberration of these genes can
result in a variety of dental defects.
Examples of pathological expression of BSP include breast cancer [230-234],
arterial calcifications [235], and kidney stones [236]. The expression of BSP in cancers
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has been associated with their calcifications and aggressive metastatic characteristics
[233, 237]. This has been specifically identified in breast cancers that have a propensity
to metastasize to bone [230]. The BSP expression in metastatic cancers suggests it is a
potent chemotactic molecule. This has been confirmed in vitro where decreased BSP
resulted in impaired metastasis of MDA-MB-231 breast cancer cells [237, 238].
Dysregulation of BSP also suggests it may be promoting the survival and/or proliferation
of these highly aggressive cancer cells. BSP has also been shown to be expressed in other
pathological conditions with ectopic mineralization, such as atherosclerosis [235].
Localization of BSP within these plaques suggests that it may have some part in
adversely promoting mineralization resulting in arterial stenosis.
OPN has also been identified within similar pathological conditions of cancer,
atherosclerotic plaques, and kidney stones, among others. OPN has been identified to be
important in mediation of the inflammatory response [239] due to its integrin-binding
capabilities [240]. It has been demonstrated that OPN promotes the migration and activity
of neutrophils during inflammation. The expression of OPN has been demonstrated to
increase in response to certain pathogens [241-244]. It is also worth noting that upon loss
of OPN in mice wound healing is altered [245]. These studies all suggest that OPN is a
critical factor in the mediation of inflammatory responses.
OPN is studied extensively in cancers as it is expressed in many conditions
including: multiple myeloma, leukemia, pancreatic cancer, and melanoma (reviewed in
[174]). OPN is strongly correlated with metastatic potential of ras-transformed NIH 3T3
cells [246] and also shown to be upregulated by β-catenin, resulting in increased
migration and tumorigenesis in epithelial cells [247]. Interestingly, in contrast to the
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phosphorylation dependent responsiveness in osteoclasts and macrophages, cancer cell
response appears to be independent of post-translational modification [248]. Similarly to
BSP, OPN has been shown to be correlated with vascular invasion. OPN has been shown
to promote VEGF-induced cell migration [249] and directly induce angiogenesis in
endothelial cells [250].
The exact role of OPN during pathological calcifications it not completely
understood, but it appears to be an inhibitor of mineral growth. OPN has been shown to
be detected in atherosclerosis [206] and highly expressed during early lesion formation
by macrophages and T lymphocytes [216]. Although the Opn-/- mouse demonstrates no
significant phenotype of atherosclerotic lesions, when it is ablated alongside MGP,
plaque growth is exacerbated dramatically [251]. As discuss above, OPN has also been
shown to be detectable in kidney stones, and is a potent inhibitor of calcium oxalate
growth. These studies confirm that OPN is an important mediator of mineral growth in
pathological calcifications.
1.6

Specific objectives and hypotheses

1.6.1

Overview
The goal of this thesis is to delineate the role of the SIBLING proteins BSP and

OPN in the mediation of biomineralization and skeletal development. Both of these
proteins have been shown to be important for the regulation of mineralization in vitro and
in vivo, but their interactions with the cells involved in biomineralization are not
completely characterized. This thesis uses a developmental model and osteogenic cell
cultures in order to clarify the roles of SIBLING proteins during biomineralization.
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The characterization of the results of loss of BSP during embryonic development
provides a more thorough understanding of its role during endochondral ossification. The
phenotype of the Bsp-/- mouse has only been characterized in adult tissues. The time of
onset of the phenotype is not yet known. Characterization of the development of the
phenotype will provide evidence to understand the role of BSP during endochondral
ossification. Herein I studied the effects of loss of BSP in the developing tibiae.
Furthermore, I investigated the phenotype of osteoblasts upon the loss of BSP, and
performed adenoviral overexpression to rescue the phenotype of Bsp-/- osteoblasts. This
study, along with the Bsp-/- mouse, will identify the role of BSP during osteogenic cell
differentiation and their biomineralization.
The characterization of the role of OPN during osteogenic mineralization has not
been fully elucidated. In order to address the role of OPN during osteogenic cell
differentiation and mineralization, Opn-/- osteoblasts were grown in cell culture and
compared to wild-type cells. Once the phenotype was characterized, the cells were then
supplemented with exogenous bovine milk OPN and OPN peptides. The characterization
of the Opn-/- osteoblasts and subsequent treatment with OPN will identify the mechanism
by which it acts to regulate osteogenic-mediated biomineralization.
Herein I identify the importance of BSP during ossification, as well as its role in
promoting osteoblast development. In a novel finding, I show that BSP appears to be
critical for normal growth plate development and chondrocyte cell-cycle progression.
Furthermore, I show that OPN is strictly an inhibitor of mineral growth in osteogenic cell
cultures. Additionally, supplementation with exogenous OPN and its functional peptides
are capable of rescuing the enhanced mineralization phenotype of the Opn-/- osteoblasts
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without affecting their differentiation characteristics. The identification of the roles of
these SIBLING proteins during the process of biomineralization can provide potential
targets for prevention or treatment of pathological calcifications.
1.6.2

Study one – Loss of bone sialoprotein impairs endochondral bone

development

Hypothesis – BSP is a positive regulator of osteogenic cell development and matrix
mineralization.

Specific Aims
1. Determine the phenotype of BSP loss during endochondral ossification.
2. Identify the cells types affected by loss of BSP.
3. Characterize gene expression characteristics upon loss of BSP.
Both chondrocytes and osteoblasts are responsible for promoting matrix deposition
and mineralization. Loss of BSP resulted in phenotypic changes that presented as delayed
ossification and mineralization. Bsp-/- mice also demonstrated an aberrant growth plate
that likely contributed to their decreased bone length. These studies demonstrated that
loss of BSP resulted in multiple cell types having delayed developmental characteristics.
There was no significant change in osteoclast activity, suggesting that BSP is not critical
to normal osteoclast activity in vivo.
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1.6.3

Study two – The role of bone sialoprotein and its functional characteristics in

osteoblast differentiation and mineralization

Hypothesis – BSP is a positive regulator of osteoblast maturation and mineralization. The
functional regions of BSP play independent roles in promoting the differentiation and
mineralization of osteoblasts.

Specific aims
1. Characterize the phenotype of Bsp-/- osteoblasts over a time-course of
development in vitro.
2. Perform adenoviral overexpression of BSP to rescue the phenotype of the Bsp-/osteoblasts.
3. Determine the effects of the functional regions of BSP on osteoblast
mineralization and differentiation in vitro.
Loss of BSP resulted in delayed osteoblast differentiation and mineralization
relative to wild-type controls. I also demonstrated lower metabolic activity of Bsp-/osteoblast cultures, suggesting these cells have decreased proliferation. Overexpression
of BSP resulted in increased expression of markers of osteoblast differentiation and
increased mineralization relative to controls. Overexpression of the BSP mutants resulted
in increased mineralization. Interestingly, N-terminal truncation and integrin-binding
inactivation both resulted in upregulation of different osteogenic genes. This suggests that
BSP may have multiple signaling motifs, the RGD integrin-binding sequence and at least
one other as yet unidentified signaling motif.
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1.6.4

Study three – Osteopontin modulates mineral formation and not osteogenic

cell development in vitro

Hypothesis – Osteopontin is an important regulatory element in mineralization, and
its loss will result in increased mineralization of osteoblast cell cultures.

Specific aims
1. Determine the phenotypic changes of primary osteoblasts upon loss of OPN.
2. Supplement the Opn-/- osteoblasts with exogenous OPN to attenuate
mineralization in the cell cultures.
3. Discern whether functional peptides of OPN can inhibit mineralization in the
Opn-/- osteoblast cell cultures.
I found that loss of OPN resulted in no physiologically relevant changes in
expression of osteoblast genes, but that there was increased mineralization in the
osteoblast cultures. Supplementation with bovine milk OPN resulted in a dramatic
reduction in mineralization while not changing expression of terminal differentiation
markers of osteoblasts. Supplementation with functional peptides of OPN rescues the
hypermineralization phenotype of the Opn-/- osteoblasts, while also not changing the
expression of marker genes of terminal osteoblastic differentiation.
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CHAPTER TWO

LOSS OF BONE SIALOPROTEIN LEADS TO IMPAIRED
ENDOCHONDRAL BONE DEVELOPMENT AND MINERALIZATION 1

1

This Chapter has been reproduced from:

E. Holm, J.E. Aubin, G.K. Hunter, F. Beier, H.A. Goldberg. 2014. Loss of bone
sialoprotein leads to impaired endochondral bone development and mineralization. (In
revision at Bone August, 2014)
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2.1

Chapter Summary
Bone sialoprotein (BSP) is an anionic phosphoprotein in the extracellular matrix

of mineralized tissues, and a promoter of biomineralization and osteoblast development.
Previous studies on the Bsp-deficient mouse (Bsp-/-) have demonstrated a significant bone
and periodontal tissue phenotype in adulthood. However, the role of BSP during early
long bone development is not known. To address this, early endochondral ossification in
the Bsp-/- mouse was studied. Embryonic day 15.5 (E15.5) wild-type (WT) tibiae showed
early stages of ossification that were absent in Bsp-/- mice. At E16.5, mineralization had
commenced in the Bsp-/- mice, but staining for mineral was less intense and more
dispersed compared with that in WT controls. Tibiae from Bsp-/- mice also demonstrated
decreased mineralization and shortened length at postnatal day 0.5 (P0.5) compared to
WT bones. There was no detectable difference in the number of tartrate-resistant acid
phosphatase-positive foci at P0.5, although the P0.5 Bsp-/- tibiae had decreased Vegfα
expression compared with WT tissue. Due to the shortened tibiae the growth plates were
examined and determined to be of normal overall length. However, the length of the
resting zone was increased in P0.5 Bsp-/- tibiae whereas that of the proliferative zone was
decreased, with no change in the hypertrophic zone length of Bsp-/- mice. A reduction in
cells positive for Ki-67, an S-phase cell-cycle marker, was noted in the proliferative zone.
Decreased numbers of TUNEL-positive hypertrophic chondrocytes were also apparent in
the Bsp-/- tibial growth plates, suggesting decreased apoptosis. Expression of the
osteogenic markers Alp1, Col1a1, Sp7, Runx2, and Bglap was reduced in the
endochondral bone of the neonatal Bsp-/- compared to WT tibiae. These results suggest
that BSP is an important and multifaceted protein that regulates both chondrocyte
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proliferation and apoptosis as well as transition from cartilage to bone during
development of endochondral bone.
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2.2

Introduction
Mammalian long bones develop through a complex and intricately regulated

process called endochondral ossification. The formation of bone initiates as a
condensation of pluripotent mesenchymal stem cells to form the template of the bone [1].
These precursor cells differentiate into chondroblasts under the regulation of the
transcription factors Sox5, 6, and 9 [2, 3]. The chondroblasts deposit a matrix composed
mainly of type II collagen and aggrecan before maturing into chondrocytes [4]. These
chondrocytes are highly proliferative and develop the early growth plate [5]. The cells
within the growth plate terminally differentiate into hypertrophic chondrocytes at the
centre of the bone while secreting type X collagen. At this point the cartilaginous anlage
calcifies around the late hypertrophic chondrocytes that secrete vascular endothelial
growth factor in order to promote blood vessel invasion, and then proceed to undergo
apoptosis [6]. This allows recruitment of osteoclasts that resorb the mineralized
cartilaginous matrix, as well as secretion of osteoid followed by its mineralization by
osteoblasts [7]. The chondrocytes at the ends of the bones continue to proliferate and
hypertrophy to regulate longitudinal bone growth, while the osteoblasts terminally
differentiate by either becoming trapped in mature bone and becoming osteocytes, or
undergoing apoptosis.
Bone sialoprotein (BSP) is an anionic phosphoprotein believed to be one of the
primary regulators of mineralization in bone and teeth. It is highly expressed by
mineralizing cells such as hypertrophic chondrocytes and osteoblasts [8-10]. BSP is a
member of the Small Integrin-Binding Ligand N-linked Glycoprotein (SIBLING) family
of proteins. This family includes osteopontin (OPN) and dentin matrix phosphoprotein
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(DMP1), both of which are derived from a common ancestor that is shared with other
calcium-binding proteins found in enamel, milk and saliva [11]. The members of the
SIBLING family are located in a syntenic gene locus that has been named the “bone gene
cluster” located on murine chromosome 5 [12]. BSP shares common features with other
members of this group, which are intrinsically disordered proteins with little or no
secondary or tertiary structure [13-15]. These proteins also contain integrin-binding RGD
(Arginine-Glycine-Aspartate) sequences and highly acidic regions composed of
(depending on the protein) poly-glutamate or poly–aspartate sequences. In BSP, the polyglutamate sequences, which are highly conserved [16, 17], are critical for hydroxyapatite
(HA) nucleation activity based on in vitro studies [18]. The RGD sequence of BSP
mediates cell attachment [19, 20] but also has been demonstrated to promote osteoblastic
cell differentiation and mineralization in vitro through cellular signaling pathways
involving focal adhesion kinase and extracellular signal-regulated kinases [21]. As such,
BSP is postulated to be an important mediator of bone mineralization.
BSP is highly expressed in developing bones during endochondral ossification
[22] and is also deposited at the mineralization front of bone and in the cement lines [23].
Overexpression of BSP downstream of a CMV promoter (CMV-BSP) in vivo resulted in
mice that are significantly smaller than their wild-type controls [24]. There are also
defects in their endochondral bones, with aberrant growth plate formation and
development. The growth plates of the CMV-BSP mice have no change in overall length,
although there was an increase in hypertrophic zone size and number of hypertrophic
chondrocytes. At 8 weeks of age, the mice also show a decrease in the proliferative zone
length. This suggests that the overexpression of BSP promotes terminal differentiation in
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these chondrocytic cells. In addition, these CMV-BSP mice have increased numbers of
osteoclasts in their trabecular bone, suggesting that BSP promotes osteoclast formation
[24]. These differences suggest that BSP is also responsible for promoting terminal
differentiation in other types of skeletal cells.
Mice deficient in BSP (Bsp-/-) also have decreased long bone length and cortical
bone thickness relative to wild-type (WT) mice at 4 months of age [25]. Conversely, they
have a higher trabecular bone density than WT mice, but an apparent lower rate of bone
turnover. This decrease in turnover could be due, in part, to a decrease in osteoclast
numbers. However, Wade-Gueye et al. demonstrated that ovarectomized Bsp-/- mice are
still susceptible to significant bone loss or osteoporosis, suggesting that BSP is not a
critical requirement for osteoclast attachment and bone resorption in vivo [26]. Bsp-/mice have decreased mineralization of cortical bone and a significant delay in cortical
bone repair following injury [27]. This process of repair in many ways mirrors bone
development and suggests a defect in endochondral bone development. Malaval et al.
noted only a minor decrease in mineralization of bone from Bsp-/- neonatal mice, and did
not report any other changes to skeletal tissues in these mice [25]. To date, there has been
no characterization of BSP’s role in early mineralization and bone development
processes.
In this study we sought to determine the role of BSP in the development of
endochondral bone. We demonstrate that lack of BSP results in delayed patterns of bone
development, which can be attributed, in part, to the reduction in the proliferation and
apoptosis of the chondrocytes within the growth plate. Additionally, we show that
expression of osteoblastic markers is reduced in the Bsp-/- endochondral bone at postnatal
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day (P0.5). Together, these data demonstrate an important role of BSP in normal bone
development and mineralization.
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2.3 Materials and methods
2.3.1

Animal protocol
Animal procedures were performed in accordance with guidelines of the Canadian

Council on Animal Care (CCAC) and Animal Care and Veterinary Services (ACVS),
University of Western Ontario, under protocol number 2008-092. Preparation and
genotyping of Bsp homozygous knock-out (Bsp-/-) and WT mice were described
previously [28]. Mice were maintained on a mixed 129/CD1 background and were fed a
standard pelleted mouse diet (2018 Tekland Global 18% protein diet, Harlan
Laboratories, USA) and tap water ad libitum. Animals used in this study were generated
by breeding heterozygous parents to produce litter-matched offspring. For statistical
analyses, the number of litter-matched animals used of each time point was as follows:
E15.5 n=6, E16.5 n=13, P0.5 n=10, P10.5 n=5.
2.3.2

Histology and immunohistochemistry
Bsp-/- and WT tibiae were harvested and prepared for histology as previously

described [29-31]. Briefly, animals were euthanized and tibiae dissected and fixed in 10%
formalin in PBS at 4°C overnight. Tissues were prepared for paraffin embedding using
standard histological processing. Longitudinal sections of the tibiae were collected at 5
µm thickness by rotary microtome and mounted on positively charged glass slides. Slides
were then deparaffinised in xylene and rehydrated for histological analyses.
Safranin O staining for the cartilage was performed as previously described [29].
Tartrate-resistant acid phosphatase (TRAP) stain was performed to identify osteoclast
activity using a commercial kit (TRAP kit, product # 387A, Sigma, Oakville, Canada) as
previously described [30]. TRAP-positive foci per scaled unit area (pixels) were
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determined. Von Kossa stain, to detect mineral, was performed using 1% silver nitrate
under ultraviolet light for 20 min. Unbound stain was removed using 5% sodium
thiosulfate for 5 min. The slides were then stained with 1% w/v alcian blue in 3% acetic
acid for 20 min, and counter-stained with 0.1% nuclear fast red for 5 min. All chemicals
used for staining were acquired from Sigma. Absolute quantification of von Kossa
staining was performed by pixel counting of total positively stained area from each
section including both trabecular and cortical bone at time points E15.5, E16.5, and P0.5.
P10.5 quantification measured the stained trabecular bone or secondary ossification
centre relative to total area. Statistical analyses were performed using independent
samples t-test (GraphPad Prism software, v4.00).
Immunohistochemistry (IHC) and immunofluorescence (IF) were performed as
previously described with some modifications [28]. Antigen retrieval was done by
heating samples to 121°C for 30 sec in 1 M sodium citrate (pH=6) in a decloaking
chamber (Biocare Medical, Concord, USA). Samples were slowly cooled to 80°C then
removed. Slides were then blocked with 5% goat serum in PBS for 1 h. Samples were
probed with primary antibody overnight at 4°C at dilutions noted below, or following
manufacturer’s guidelines. After washing, secondary antibody was used according to
manufacturer’s protocol then developed using peroxidase substrate. Slides were
dehydrated through graded ethanol and cleared in xylene prior to mounting.
Reagents for IF and IHC were: rabbit anti-mouse BSP (1:200, courtesy of Renny
Franceschi, University of Michigan, Ann Arbor, USA); rabbit anti-Ki-67 (1:200,
ab15580, Abcam, Toronto, Canada); In Situ Cell Death Detection Kit (11684795910,
version 16, Roche, Laval, Canada); rabbit anti-mouse PECAM-1 (sc-1506-R, Santa Cruz,
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Dallas, USA); and rabbit anti-p57 (sc-8298, Abcam). The secondary probe and
development was performed using ABC staining system (sc-2018, Santa Cruz) according
to manufacturer directions.
2.3.3

Histomorphometry
Proximal growth plates of Bsp-/- and WT tibiae were evaluated by two

independent, blinded observers. Ki-67-positive cells were quantified in a 100x100 µm
box along the midline of the growth plate at a distance of 300 µm from the end of the
hypertrophic zone. Ki-67-positive cells were quantified and normalized to total number
of cells per area by ImageJ (v1.46r, NIH, USA). Terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) quantification was performed by enumerating total
numbers of TUNEL-positive cells in the hypertrophic zone using ImageJ. Overall bone
length was measured using images of tibiae taken using a LED2500 dissection
microscope with integrated EC3 digital camera (Leica Microsystems GmbH, Concord,
Canada) and measuring length digitally on ImageJ, followed by converting the length in
pixels to µm. Statistical analyses were performed using independent samples t-test
(GraphPad Prism).
2.3.4

Microdissection and real-time quantitative PCR
Mouse tibiae were dissected as shown in Figure 2A. Briefly, bones from neonatal

mice were separated such that growth plate chondrocytes were pooled into one of two
populations: the resting and proliferative zone (RP) or the hypertrophic zone and
endochondral bone (HEB). These tissues were pooled and the total RNA was isolated
from bones using RNeasy according to the manufacturer’s protocol (74104, Qiagen,
Toronto, Canada). Purified RNA was then reverse transcribed using SuperScript II RT kit
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according to the manufacturer’s guidelines (18064, Life Technologies). PCR reactions
were performed as previously described [32]. We used the two-step Master mix
(4440038, Life Technologies) on a 7900 HT system (Life Technologies) according to
manufacturer specifications. Probes used for gene expression are shown in Table 1. Beta2-microglobulin (B2m) was used as a reference gene for normalization of expression and
relative quantification. B2m was confirmed as a reference gene by validating its
expression using 18s ribosomal RNA (18s) and determining there was no change in
expression patterns between tissues and genotypes (data not shown). We performed
statistical analysis using independent samples t-test in Prism.
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Table 2.1: Genes assayed using real-time quantitative PCR alongside their TaqMan
primer codes. A. The primers used for assaying osteoblast markers. B. Primers used for
assaying chondrocyte expression. C. Target genes for assaying modeling alongside their
associated product numbers.
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2.4 Results
2.4.1

Bone sialoprotein is expressed during development
Expression of BSP in the developing skeleton was assessed in the immature bones

of WT mice by immunohistochemistry (IHC). BSP was detected in mineralizing tissues
of the WT tibiae from day E15.5, E16.5, and P0.5 and was deposited throughout the
diaphysis of the developing bone (Figure 1A, B, &C). We did not detect BSP protein in
any of the matched sections from the Bsp-/- mice. We confirmed Bsp expression in the
WT tibiae and its absence in the Bsp-/- tissues by performing microdissections to isolate
the resting and proliferative zones (RP fraction) from the hypertrophic zone and
endochondral bone (HEB) fraction, as depicted in Figure 2A. Following dissection, we
performed qPCR on the separate fractions and assayed for expression of osteogenic and
chondrogenic markers (see below). Bsp mRNA was detectable in the RP fraction at 20%
of that observed in the HEB fraction in WT samples (Figure 2B). Expression of the
hypertrophic chondrocyte markers, ColX and Mmp13, confirmed the dissections were
performed without significant cross-contamination, i.e., these markers were not detected
in the RP fraction (Figure 2C).
2.4.2

Mineralization is delayed in the tibiae of Bsp-/- mice
To determine whether mineralization was affected in the Bsp-/- mice, histological

analysis was conducted on the long bones of Bsp-/- mice and control littermates. By von
Kossa and alcian blue staining, delays in mineralization were observed at multiple stages
of early bone development in the Bsp-/- mice (Figure 3). In E15.5 WT mouse tibiae,
mineral deposition was concentrated around the bone collar, with some staining in late
hypertrophic cartilage, whereas mineralization was absent in the Bsp-/- tibiae (Figure 3A).
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Figure 2.1: BSP is expressed in mineralizing tissues during development, but not in
Bsp-/- mice. Immunohistochemical staining with anti-BSP antibodies at E15.5 (A), E16.5
(B), and P0.5 (C) tibiae show where BSP is detected (brown) in the WT tibiae, and
confirms its absence in the Bsp-/- mice. All sections were counterstained with methyl
green. (E15.5 n=6, E16.5 n=13, P0.5 n=10. Scale bar is 100 µm in all panels).
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Figure 2.2: Analyses of Bsp expression in neonatal endochondral bones by
microdissection. A schematic of a neonatal bone demonstrates where the bones were cut
(red lines) (A). This separated the bone into two sections, the central hypertrophicendochondral bone (HEB), and the resting and proliferative (RP) fraction. Real-time
qPCR demonstrated expression of Bsp in RP and HEB fractions of WT bones and its
absence in Bsp-/- tissues (B). Confirmation of exclusion of the hypertrophic zone from the
RP fraction was done by performing qPCR for ColX and Mmp13 (C). (n=5, error bars are
SEM, * denotes p<0.05)
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Mineralization was evident at E16.5 in the Bsp-/- bone, but was reduced by 30% (Figure
3D) and more evenly dispersed throughout the diaphysis compared to the well-defined
mineralization pattern at the bone collar in WT sections, supporting a delay in
mineralization in Bsp-/- bone (Figure 3B). At P0.5 Bsp-/- bone exhibited a weaker staining
intensity than the WT bone which, based on analysis of total area stained, translates into a
40% decrease in overall mineral content (Figure 3C & F). P0.5 Bsp-/- bone samples
showed a slight but significant 5% reduction in overall tibia length (Figure 3G). The
developmental delay persisted throughout secondary ossification, as demonstrated by the
well developed pattern observed in WT P10.5 bone compared to that in the age matched
Bsp-/- bone (Figure 3G). Quantification of mineral at P10.5 demonstrated a 40% reduction
in mineral of the trabecular bone (Figure 3H) and a 60% reduction in mineral content of
the secondary ossification centres (Figure 3I) relative to total area.
2.4.3

Modeling of the developing tibiae is unchanged in the Bsp-/- mouse
To determine whether the delay in ossification was related to a modeling

impairment, we analyzed tartrate-resistant acid phosphatase (TRAP) activity in the
developing bone. In both E16.5 (data not shown) and P0.5 tissue, there was no detectable
difference in the number of TRAP-positive foci in Bsp-/- versus WT (Figure 4A & B). To
further delineate the characteristics of modeling in these developing tibiae, we
investigated expression of markers of bone modeling, Rankl, Opg, and Vegfa (Figure 4C
& D). No significant difference in Rankl or Opg expression was observed in Bsp-/- versus
WT bones. Additionally, the Opg/Rankl expression ratio is unchanged between
genotypes. Vegfa expression was decreased by 40% in the Bsp-/- as compared to WT
bones, suggesting a delay of vascular invasion in Bsp-/- bone.
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Figure 2.3: Mineralization is impaired in the developing tibiae of the Bsp-/- mouse.
Alcian blue and von Kossa (black) staining of E15.5 (A), E16.5 (B), and P0.5 (C) tibiae
show location of mineral deposition in the WT and Bsp-/- tissues. Sites of secondary
ossification of P10.5 Bsp-/- mouse tibiae compared to the WT bones (D). Quantification
of mineral content from E16.5 (E), P0.5 (F), P10.5 trabecular bone (H), and secondary
ossification centres (I) tibiae of the WT and Bsp-/- bones. Measurements of neonatal tibia
lengths from WT and Bsp-/- mice (G). (E15.5 n=6, E16.5 n=13, P0.5 n=10, P10.5 n=5.
Scale bar is 100 µm in all figures. * denotes significance where p<0.05)
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Figure 2.4: Modeling of the developing bone by osteoclasts appears unchanged in
the Bsp-/- tibiae. Representative images of P0.5 bones show TRAP-positive foci in the
developing tibiae at low (A), and high-magnification (B). Quantification of TRAPpositive foci per scaled unit area (pixels) (C). qPCR of Rankl, Opg, Opg/Rankl
expression ratio, and Vegfα from HEB fraction of the WT and Bsp-/- bones (D). (P0.5
n=5, qPCR n=5. Scale bars are 100 µm. * denotes significance where p<0.05)
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2.4.4

Ratios of growth plate zone lengths are altered in the Bsp-/-tibiae
Due to the reduction in overall bone length, we next investigated the growth plate

for physiological abnormalities. Whereas there was no difference in the overall length of
the growth plates between genotypes, detailed analysis indicated that there were
significant differences in lengths of the individual zones between the growth plate of P0.5
Bsp-/- and WT bones (Figure 5). The resting phase was 20% longer in the Bsp-/- versus
WT tibiae, with a reciprocal decrease in length of the proliferative zone, and no change in
the hypertrophic zone (Figure 5A & B). To determine the extent of the proliferation
defect, we quantified cells expressing the S-phase cell-cycle marker Ki-67. There was a
40% reduction in Ki-67-positive cells in the Bsp-/- tibiae as compared to WT tibiae,
suggesting a marked decrease of proliferating cells within the proliferative zone, or a
delay in cell-cycle progression (Figure 5C & D). Finally, we investigated hypertrophic
chondrocyte apoptosis and observed a 40% decrease in TUNEL-positive cells in the Bsp/-

versus WT tibial sections (Figure 5E & F).
To investigate expression of chondrocyte markers of differentiation, the

microdissection fractions previously described were used. The RP fraction was assayed
for expression of developmental markers of chondrocyte development Alp1, Col2a1,
Acan, Runx2, and Sox9 and no differences were seen between genotypes (Figure 6). As
expected, Bsp expression was undetectable in the Bsp-/- RP fraction, while present in the
WT tissue. As indicated above, there was also no difference in expression of the
hypertrophic markers ColX and Mmp13 in the HEB fraction (Figure 2C).
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Figure 2.5: The growth plates of Bsp-/- neonatal tibiae show significant aberrations
and delayed progression through the cell-cycle. Safranin O staining of WT and Bsp-/P0.5 tibiae show chondrocytes within the proximal growth plate (A). Quantification of
the resting, proliferative, and hypertrophic zone lengths of neonate tibiae from WT and
Bsp-/- animals (B). Immunofluorescent staining of Ki-67 within the growth plates,
denoting cells in S-phase of the cell cycle, high-magnification insets are shown alongside
their respective genotypes (C). Quantification of the number of Ki-67-positive cells in the
proliferative zone relative to total cell number (D). Immunofluorescent detection of
TUNEL in hypertrophic chondrocytes of the growth plate, high-magnification insets are
shown alongside their respective genotypes (E). Quantification of the total number of
TUNEL-positive cells in the tibiae (F). Scale bar is 100 µm in all figures. n=10, * denotes
significance where p<0.05.
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Figure 2.6: Expression of chondrocyte marker genes in the neonatal growth plate of
the Bsp-/- mouse is unchanged. Quantitative real-time PCR probing chondrocyte
markers from the RP fraction of growth plate of tibiae from P0.5 animals. (n=5, error bars
are SEM, * denotes p<0.05)
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2.4.5

Osteoblast marker expression is impaired in Bsp-/- tibiae
Since there was no change observed in the chondrocyte markers, we next

examined markers of osteoblastic development in the HEB fraction from P0.5 mouse
tibial bone (Figure 7). The expression of many of these markers was decreased in the
neonatal Bsp-/- compared to WT tibiae: Col1a1 was reduced to approximately 50%, Sp7
to 40%, Alp1 and Runx2 to 60%, and Bglap to 30%. No differences were detected in
Dmp1 or Spp1 transcript levels in these samples at this time point.
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Figure 2.7: Expression of osteogenic genes is reduced in the neonatal tibiae of Bsp-/as assayed by qPCR. Quantitative real-time PCR analyses of osteoblast marker
expression. Total RNA was isolated from the HEB fraction of tibiae from P0.5 mice.
(n=5, error bars are SEM, * denotes p<0.05)
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2.5 Discussion
Malaval et al. have characterized the defects in the long bones of Bsp-/- mice [25].
At 4 months of age, there are decreases in mineral density, overall bone length and
cortical bone thickness but an increase in trabecular bone density. They suggested that
the increase in trabecular bone density was caused by a deficiency in bone turnover by
the osteoclasts [25]. Malaval and colleagues also examined the mineral densities of
younger and older Bsp-/- bones. In neonatal Bsp-/- mice the mineral density is decreased,
whereas at 1 year of age the mineral content appears normal. In our study, we focused on
earlier stages of development to determine when and how BSP deficiency first affects
skeletal development. We report a similar phenotype of decreased bone length at the
early time point of P0.5, and a decrease in mineral content of the embryonic and neonatal
bones. We also observed a temporal delay in onset of mineralization during long bone
development. Bsp-/- mice do not have detectable levels of mineral in their tibiae at E15.5,
in contrast to the substantial level in the WT bone. Even following the initial deposition
of mineral in the Bsp-/- bone, it does not appear to be organized around the bone collar as
seen in the WT tibia; instead the mineral appeared to be more evenly distributed
throughout the Bsp-/- tibia. The delay in development was not restricted to the sites of
primary ossification, but also occurred at sites of secondary ossification as seen in the
P10.5 tibiae of the Bsp-/- mouse. These delays indicate that BSP plays an important role in
controlling the timing of mineral onset and mineral density in vivo.
BSP has previously been shown to be a promoter of osteoclast formation and
resorption [24, 33], and the CMV-BSP mice, which overexpress BSP, have enhanced
osteoclast activity in vivo [24]. Based on these studies, and the evident delay in
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endochondral ossification in the Bsp-/- mice, we examined markers of osteoclast activity.
We did not observe any difference in the number of TRAP-positive foci in Bsp-/- versus
WT mice, nor for the ratio of Opg/Rankl expression, known modulators of osteoclast
formation, suggesting that there is no impairment in osteoclast formation in the absence
of BSP. This is also supported by previous studies in which Bsp-/- mice were challenged
by tail suspension [25] and ovariectomy [26] with observed loss of bone similar to that in
controls. Of note, the observed reduction in Vegfα expression, suggests that BSP may be
a promoter of vascular invasion during endochondral ossification, in agreement with
previous studies demonstrating that BSP promotes angiogenesis [34].
To better understand and characterize the decrease in length of the tibiae observed
in the newborn Bsp-/- mice, we examined the stages of chondrocyte development within
the growth plate. While there was no difference in the overall length of the growth plate
in newborn Bsp-/- versus WT mice, in agreement with the first published work on the Bsp/-

mice by the Malaval group [25], we observed the resting and proliferative zone lengths

were increased and decreased, respectively, with no change in hypertrophic zone length
in the P0.5 Bsp-/- growth plates. This differs from the recent work published by Malaval’s
group 2 where they observed reduced thickness of both the growth plate and the
hypertrophic zone length in newborn Bsp-/- mice [35]. At present, we cannot explain these
apparent differences; however, differences in housing conditions, animal chow, and/or
breeding strategies could be responsible. The overexpressing BSP-CMV mouse model
demonstrated a similar phenotype of decreased proliferative zone length, although it had

2

After submission of this manuscript, Reference [35] by the Malaval group was published
online.
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an increased hypertrophic zone length [24]. The decreases of the proliferative zone length
in both the Bsp-/- and CMV-BSP mice appear surprising. However, our data suggest that
the reductions in length are due to different mechanisms. In the Bsp-/- mice it may be
caused by delayed entry of chondrocytes into the proliferative zone which leads to the
observed increased length of the resting zone. In the BSP-CMV mice there may be an
accelerated exit of the chondrocytes from the proliferative zone, leading to the observed
increased hypertrophic zone length [24].
Analysis of osteoprogenitor development has shown that BSP is expressed at two
distinct times: the first during the proliferative immature osteoprogenitor phase, and the
second during maturation from preosteoblasts to osteoblasts [36]. Drawing a parallel
between the chondrocytes and osteoblasts, we propose the following model for BSP’s
role in chondrocyte maturation within the growth plate. Low-level BSP expression in the
chondrocytes initiates cell proliferation from the resting phase while also helping to
maintain their proliferative capacity as they mature. Increased BSP expression in the
hypertrophic chondrocyte phase then promotes terminal differentiation and apoptosis.
This model accounts for the differences seen in both the Bsp-/- mice and the CMV-BSP
mice.
Understanding the expression characteristics of osteogenic markers in the
developing bone provides additional insight into the state of development in the Bsp-/mouse. Previous work by Malaval et al. showed that the majority of markers are
unchanged (Alp, Col1, Sp7, Bglap, Opg, Rankl) in the fully developed femurs of 4 month
old Bsp-/- mice [25]. However, Spp1 was significantly decreased in the mature Bsp-/bone. In our study, the mineralized regions of neonatal tibiae from the Bsp-/- mice show a
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different picture of osteogenic marker expression during development: a normal
expression of Spp1 but the decreased expression of other osteogenic cell markers (Alp1,
Col1a1, Sp7, Runx2, Bglap) suggesting fewer mature osteoblasts in the Bsp -/- mouse.
This is similar to the recently published work on young P6 whole bone extracts from the
Bsp-/- mouse [35]. This discrepancy in expression patterns between developing and
mature bone suggests multiple roles for BSP at different stages of development. Mature
bone contains significant levels of BSP protein [23], but the Bsp transcript is at low or
undetectable levels [9]. However, upon challenge it becomes apparent that there are
deficiencies in the Bsp-/- mouse. Using a long bone defect model, Malaval et al
demonstrated that bone formation was delayed in 4 month old Bsp-/- mice compared to
the WT mice [27]. In separate studies, using critical-size calvarial defects in rats, addition
of BSP in a collagen-based scaffold enhanced repair [37]. Due to the commonalities
between bone repair and development, we can speculate that the loss of BSP results in
delayed de novo bone deposition similar to our model of delayed endochondral
ossification.
BSP is present in a number of other mineralized tissues where its roles are yet to
be defined. Recently, we have shown that BSP is involved in acellular cementum
formation and is integral to proper periodontal ligament to tooth attachment [28]. In the
absence of BSP, the periodontal ligament is disorganized resulting in tooth and alveolar
bone resorption. Both the loss of acellular cementum and the phenotype shown herein
support the concept that BSP plays a role regulating mineralized tissues and their
consequent interactions with the neighbouring non-mineralized tissue. We are currently
investigating the implications of BSP loss in these situations.
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Previous studies investigating the role of BSP in early bone have provided some
valuable insight, but these experiments lacked a temporal characterization of the
developmental process. This study has shown that BSP plays an important role in bone
development and promotes cell-cycle progression of chondrocytes. BSP promotes normal
endochondral bone development, and its absence correlates with delayed initiation of
mineralization. Together these data suggest that BSP has a more widespread role in
endochondral bone development than previously shown. These differences highlight the
need to further our understanding of the roles BSP plays in mineralized tissue
development and repair.
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CHAPTER THREE

THE ROLE OF BONE SIALOPROTEIN IN OSTEOBLAST
DIFFERENTIATION AND MINERALIZATION
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3.1

Chapter Summary
Bone sialoprotein (BSP) is an anionic phosphoprotein expressed by cells within

mineralized tissues and is a mediator of biomineralization and osteogenic development.
Specific motifs that have been shown to be important for the functional properties of BSP
include: a sequence within the N-terminal domain responsible for collagen binding, polyE containing regions responsible for mineral binding and nucleation, and an RGD
integrin-binding sequence that promotes cell attachment and differentiation. However,
the importance of these individual motifs has not been investigated in osteoblast cell
cultures without endogenous BSP. To address this, adenoviral transduction of BSP and its
mutants was performed in osteogenic cells from the Bsp-/- mouse to study their response
to overexpressed BSP. Compared to wild-type, Bsp-/- osteogenic cells in culture showed
delayed mineralization and expression of osteogenic genes, and decreased metabolic
activity. Overexpression of wild-type and functional-domain altered BSP forms in the
Bsp-/- osteogenic cells resulted in increased mineralization relative to the empty-vectortreated (EV) Bsp-/- cells. Overexpression of wild-type BSP enhanced gene expression of
markers of osteoblasts relative to the EV-treated Bsp-/- cultures, while the collagenbinding deletion and integrin-binding mutation resulted in increased expression of only
some of these genes. These studies demonstrate that loss of any individual functional
motif of BSP is insufficient to impair its positive differentiation and mineralization
activity in osteogenic cultures.
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3.2

Introduction
Bone sialoprotein (BSP) is an anionic phosphoprotein expressed in mineralized

tissues including bone, hypertrophic cartilage, dentin, and cementum of teeth [1-3]. BSP
comprises up to 10% of the extracellular matrix mineral-binding proteins secreted by
osteoblasts [4]. Within bone, BSP has been shown to be expressed by mineralizing cells
such as hypertrophic chondrocytes and osteoblasts [1-3]. BSP is a member of the Small
Integrin-Binding Ligand N-Linked Glycoprotein (SIBLING) group of proteins. Other
members include osteopontin (OPN), dentin matrix protein (DMP1), dentin
phosphoprotein (DPP), dentin sialoprotein (DSP), and matrix extracellular
phosphoglycoprotein (MEPE). The proteins belonging to this group are thought to be
mediators of biomineralization and mineralized tissue development.
Members of the SIBLING group of proteins share a number of common features.
They are intrinsically disordered proteins with little or no secondary or tertiary structure
[5-7]. These proteins also contain the integrin-binding RGD (Arginine-GlycineAspartate) sequence responsible for promoting cell adhesion and signaling. Each protein
has highly acidic mineral binding regions that may contain either poly-glutamate or poly–
aspartate sequences. In BSP, the highly conserved poly-glutamate sequences have been
shown to be critical for hydroxyapatite (HA) nucleation in vitro [7, 8].
The functional regions of BSP have been shown to mediate mineral nucleation in
cell-free studies and osteogenic development in cell culture. As indicated, the nucleation
of hydroxyapatite by BSP is dependent on its highly acidic poly-glutamate sequences [8,
9]. The substitution of these poly-E sequences to poly-A resulted in a 90% loss of
nucleation potency [7]. In addition, the phosphorylation of BSP has been demonstrated to
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increase its nucleation potency by increasing the electronegative charge [7]. Specifically,
serine-135 has been demonstrated to be a critical phosphorylation site that increases the
nucleation potency of BSP by ten-fold in a steady state collagen-gel system [10]. It is
thought that in order to direct mineralization, BSP should bind to collagen with high
affinity. BSP has an N-terminal collagen-binding motif (residues 18-45) [11], and when
BSP is truncated in this domain, the resulting protein consisting of residues 28-300 is
unable to bind collagen. Additionally, when bound to collagen BSP shows increased HA
nucleation potency in vitro [12].
Not only can BSP direct HA nucleation, but it has also been demonstrated to
mediate cellular interactions via the integrin-binding RGD sequence [13, 14]. This
sequence has been demonstrated to promote osteoblastic cell attachment [15],
differentiation [16], and migration [17]. Binding of BSP to the αvβ3 integrins of
osteoblasts has been shown to result in signaling through the focal adhesion kinase
(FAK) and extracellular signal-regulated kinases (ERK) pathway [18]. These studies
demonstrate that BSP has multiple motifs that each have functions in the mediation of
osteogenic cell differentiation and mineralization.
Mice ablated for the Bsp gene (Bsp-/-) have decreased long bone length and
cortical bone thickness relative to wild-type (WT) mice at 4-months-of-age [19]. Bsp-/mice also have decreased mineralization of cortical bone and delayed repair following
injury [20]. We have documented a delay in mineralization and expression of markers of
osteoblast maturation during endochondral bone development (Chapter 2). These studies
suggest that loss of BSP impairs the development of osteoblasts in vivo. Similarly,
overexpression of BSP in mice (CMV-BSP) has resulted in shortened long bones and
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decreased calvarial thickness [21]. The phenotypic differences in both of these mice
suggest that BSP is a mediator of both osteogenic cell development and matrix
mineralization.
Osteogenic cells have been isolated from transgenic mice in order to study the
phenotype upon loss and overexpression of BSP in cell culture. Malaval et al studied
mesenchymal-derived Bsp-/- osteoblasts and demonstrated a decreased number of
mineralized nodules and delayed expression of osteoblastic markers of differentiation
[19]. Similarly, osteoblasts from the CMV-BSP mouse were shown to have increased
mineralization and number of bone nodules per well [21]. Both of these studies agree
with previous work on MC3T3-E1 preosteoblastic cells showing that adenoviral
overexpression of BSP increased mineralization and promoted terminal differentiation in
these cells as compared to the empty vector control [22]. The reduction of endogenous
BSP expression in this study by shRNA resulted in decreased mineralization and gene
expression of osteoblast markers [22]. These studies suggest that BSP is a promoter of
both osteoblast development and mineralization.
The role of BSP and its aforementioned functional regions have yet to be
elucidated upon overexpression in osteoblasts without interference from endogenous
BSP. In this study, we first characterized the phenotype of the Bsp-/- osteoblasts,
demonstrating that the loss of BSP results in delayed mineralization, decreased metabolic
activity, and delayed osteoblastic marker expression. We then performed adenoviral
transductions of wild-type BSP and its functional domain mutants in order to examine
their roles in osteoblast differentiation and mineralization. Our experiments demonstrated
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that the loss of any single region was insufficient to impair its activity promoting
mineralization and osteoblast differentiation in vitro.
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3.3

Materials and methods

3.3.1

Animal protocol
Animal procedures were performed in accordance with guidelines of the Canadian

Council on Animal Care (CCAC) and Animal Care and Veterinary Services (ACVS),
University of Western Ontario. Preparation and genotyping of Bsp homozygous knockout (Bsp-/-) and wild-type mice were described previously [23]. Mice were maintained on
a mixed 129/CD1 background and were fed a standard pelleted mouse diet (2018 Tekland
Global 18% protein diet, Harlan Laboratories, USA) and tap water ad libitum.
3.3.2

Cell culture and in vitro assays
Isolation and culture of mesenchymal stromal cells (MSCs) was performed as

previously described with minor modifications [19]. Cells were isolated by flushing the
femurs of 8-10 week old mice and were allowed to selectively adhere to T-80 flasks
(Nunc, Roskilde, Denmark) for 3 days in Iscove’s Modified Dublecco’s Medium
(IMDM) with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL
streptomycin (all reagents from Life Technologies, Burlington, ON, Canada). Media was
changed every 48 hours. At 70% confluence, cells were passaged into 24- and 96- multiwell dishes (Nunc) at a density of 1 x 104 cells/cm2. The cells were allowed to proliferate
for three days and were then grown in mineralizing media containing alpha minimal
essential medium (αMEM) with 10% FBS, 100 U/mL penicillin, 100 µg/mL
streptomycin, and supplemented with 50 µg/mL ascorbate (Sigma-Aldrich, Oakville,
Canada), and 2 mM glycerol-2-phosphate (G2P, Sigma-Aldrich). At least three
independent experiments were performed with each done in triplicate.
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Cell metabolic activity was measured using alamarBlue® (Life Technologies)
reagent. The main constituent is resazurin which produces a fluorescently-active
metabolite in linear proportion relative to cell number [24, 25]. Fluorescence was
measured with excitation and emission wavelengths of 570 nm and 585 nm, respectively,
on a Tecan Safire plate reader (Tecan Group Ltd, Männedorf, Switzerland).
Mineralization was assayed using multiple methods: Alizarin red S, calcium
quantification, and von Kossa. Cells were fixed in anhydrous ethanol for 10 minutes at 20°C. Alizarin red staining was performed using 500 µL of 1% w/v Alizarin red S dye
(Ricca Chemical Company, Arlington, USA) in water and was incubated for 10 minutes
at room temperature. Unbound stain was removed by washing with deionized water, and
plates were then allowed to dry overnight. Images of wells were taken using a LED2500
dissection microscope with integrated EC3 digital camera (Leica Microsystems GmbH,
Concord, Canada). Dye was then extracted using 1 mL of 0.6 M HCl, 0.7M sodium
dodecyl sulphate (SDS) for 1 hour while shaking. A volume of 200 µL was transferred to
a 96-well plate and absorbance measured at 415 nm on an iMark plate reader (BioRad,
Mississauga, Canada). Concentration was determined by standard curve of alizarin red S
diluted in extraction solution. Von Kossa and alkaline phosphatase staining was
performed as described previously [26]. Briefly, cells were first stained for alkaline
phosphatase activity using naphthol and red violet, then washed thoroughly with
deionized water. The mineral was then stained using 2.5% w/v silver nitrate and exposed
to fluorescent light for 1 hour, and washed with deionized water. Calcium determination
was performed using QuantiChrom™ Calcium Assay Kit (DICA-500, Bioassay Systems,
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Hayward, CA, USA) according to the manufacturer’s protocol. Spectrophotometric
readings were taken at 612 nm on the Safire plate reader.
3.3.3

Adenovirus preparation
Adenovirus was produced using the pAd⁄CMV⁄V5-DEST™ Gateway® Vector

Kit (Life Technologies) according to manufacturer guidelines. Briefly, Bsp and the
mutants that were used were previously prepared in pET28a plasmids [7, 10, 11, 18, 22].
Bsp was then cloned into the pAd⁄CMV⁄V5-DEST vector. The vector with BSP was then
linearized and transfected in HEK-293 (ATCC, Manassas, VA, USA) cells using
FuGENE® HD (Promega, Madison, WI, USA) according to manufacturer guidelines.
Cells were then scraped and transferred to a centrifuge tube and repeatedly frozen in
liquid nitrogen and thawed at 37°C three times in order to lyse the cells and release the
adenovirus. Cell debris was pelleted and the supernatant containing the adenovirus
transferred to a clean tube. This crude extract was then used to infect further HEK-293
cells to increase adenoviral concentration. The adenovirus was recovered as described
above and then purified using a chromatographic based system, Adeno-X™ Maxi
purification kit (Catalogue number 631533, Clontech, Mountain View, CA, USA),
according to the manufacturer’s guidelines. Following purification, adenovirus titres were
measured using Adeno-X™ Rapid Titer Kit (Catalogue number 632250, Clontech).
Adenovirus was then stored at -80°C until use.
3.3.4

Adenoviral transduction of Bsp-/- osteoblasts
MSCs were isolated and cultured as above. Adenoviral transduction was

performed in antibiotic-free media during passaging. Viral titration assays were
performed and an ideal multiplicity on infection (MOI) was determined to be 300.
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Briefly, cells from the T-80 flasks were resuspended in serum-free IMDM following
pelleting and 300 adenoviral particles per cell were added. The cells were then transferred
into plates at a density of 1 x 104 cells/cm2, and left to transduce for 2 hours. IMDM with
3% FBS was then added to give a final concentration of 2% FBS in IMDM and the cells
were left overnight. The following morning the media was removed and the cultures were
washed with HBSS three times. The cells were then provided with 10% FBS in IMDM to
recover for two days. Following recovery MSCs were induced to begin differentiation
using osteogenic media as described above, and this was counted as day 0.
Adenovirus experimental cultures are labelled as follows: WT is untreated
osteoblasts from WT mice; KO are untreated cells from the Bsp-/- mouse; Adenoviral
overexpression of BSP and mutants in Bsp-/- osteoblasts with empty-vector (EV), wildtype BSP (BSP), N-terminal truncated BSP (-28), RGD mutated to KAE (KAE), poly-E
to poly-A mutation (EA), and S136A mutation (SA).
3.3.5

Real-time quantitative PCR
Total RNA was isolated from cells using TRIzol (Life Technologies) according to

manufacturer’s guidelines. PCR reactions were performed using One-step Master mix
(4309169, Life Technologies) on a 7900 HT system (Life Technologies) according to
manufacturer guidelines. Gene expression assays of Alp1, Col1a1, Sp7, Runx2, Bglap,
Opn, Dmp1, Ibsp were performed using Taqman probes (Life Technologies). Beta-2microglobulin (B2M) was used as a reference gene for normalization of expression and
relative quantification. These genes and their protein names are shown in Table 1.
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3.3.6

Statistical analyses
Statistical analysis was performed using a one-way or two-way ANOVA with

post-hoc Tukey’s test using GraphPad Prism. At least three independent experiments
were performed in triplicate.
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Table 3.1: Genes and their TaqMan product codes used for real-time quantitative
PCR

120

Figure 3.1: Linear schematic of BSP forms used in adenoviral overexpression. (A)
wild-type BSP, (B) N-terminal truncated BSP unable to bind collagen (-28), poly-E
mineral binding and nucleation sites mutated to poly-A (EA), S135 phosphorylation site
mutated to A (SA), RGD integrin-binding sequence mutated to KAE.
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3.4

Results

3.4.1

Loss of BSP results in impaired mineralization and maturation of osteoblasts
The difference in mineralization between the Bsp-/- and WT osteoblasts was first

examined. Alkaline phosphatase (red) and von Kossa (black) staining demonstrated that
there was a decrease in mineral and trend of decreasing alkaline phosphatase-positive
area in the Bsp-/- cells when compared to the WT cells (Figure 3.2A). A decrease in
mineral content was also apparent after staining the Bsp-/- cell cultures with alizarin red S
(Fig 3.2A). Extraction of alizarin red dye and spectrophotometric quantification showed
that the Bsp-/- cells had a reduction of mineralization of approximately 50% relative to the
control cells at weeks 3 and 4 (Figure 3.2B). This defect in mineralization of the Bsp-/osteoblasts is also apparent at early time points of days 3, 6, and 9 as measured by
fluorometric calcium detection (Figure 3.2C). A 10% decrease in metabolic activity of
Bsp-/- cells was also observed, suggesting a decrease in their proliferation relative to the
WT controls (Figure 3.2D).
3.4.2

Osteogenic marker expression is delayed in the Bsp-/- osteoblasts
Following the determination of decreased mineralization and metabolic activity,

we investigated the gene expression of osteoblast markers of maturation. Early markers,
Alp1 and Col1a1 (Figure 3.3A), and transcription factors Runx2 and Sp7 were unchanged
in Bsp-/- mice compared to controls (Figure 3.3B). Figure 3.2C shows that there was a
peak in Opn expression in the WT cells at day 14, which is only reached by the Bsp-/cultures one week later at day 21. The expression of Opn by the Bsp-/- cultures is higher
at day 28 compared with the WT cells. Bglap expression is reduced in the Bsp-/osteogenic cultures at days 11, 14, and 28 relative to the control cells. There was no
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Figure 3.2: Bsp-/- osteoblasts have reduced mineralization and metabolic activity.
Alkaline phosphatase (red) and von Kossa (black) stains (upper half of A) and alizarin
red stains (lower half of A) of osteoblast cultures at weekly time points. (B)
Spectrophotometric quantification of alizarin red dye at 415 nm extracted from Bsp-/(dotted line) and WT (solid line) cultures at weekly time points. (C) Early time point
fluorometric calcium quantification at days 3, 6, and 9. (D) Osteogenic culture metabolic
activity assayed using alamarBlue when plated and following induction with
differentiation medium. (n=5, *p<0.05)
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Figure 3.3: The expression of late osteogenic markers is delayed in the Bsp-/osteoblasts. Quantitative real-time PCR was performed to assay gene expression of early
osteoblast markers (A), transcription factors (B), and mature osteoblast markers (C). The
expression of all genes are normalized to B2m. (n=5, *p<0.05)
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change in Dmp1 expression between genotypes. Bsp expression was undetectable in the
Bsp-/- osteoblasts and it increases over time in the WT cultures, as expected.
In order to confirm that the cells were not undergoing adipogenesis or
chondrogenesis, we examined Pparγ and Sox9 (Figure 3.4). Pparγ expression is 20%,
40%, and 60% higher in the Bsp-/- osteogenic cultures at days 14, 21, and 28,
respectively. There was no change in Sox9 expression in the Bsp-/- cultures relative to the
WT cells.
3.4.3

Adenoviral transduction efficiency and BSP expression
Titration to determine the appropriate multiplicity of infection of adenoviral

particles was performed by treating WT MSC-derived osteoblasts with EV adenovirus
expressing LacZ. A transduction efficiency of 70% was determined at an MOI of 300 by
dividing LacZ-positive cells (blue) by total number of cells (Figure 3.5A). Expression
levels at 24 hours post-induction in the serum-free cell culture media was performed by
immunoblot for BSP (Figure 3.5B).
3.4.4

BSP mutants rescue the Bsp-/- mineralization defects
Transduction of the Bsp-/- cells with adenovirus resulted in decreased

mineralization when treated with EV relative to their untreated controls (Figure 3.6A).
BSP- and mutant-treated cells showed no significant difference in mineralization
compared to the EV-treated Bsp-/- osteoblasts at week 2 (Figure 3.6B). However, at
weeks 3 and 4 there is more mineralization in the BSP- and mutant-treated Bsp-/- cells
compared to the EV-treated Bsp-/- osteogenic cultures (Figure 3.6C, D). Of all the mutantBSP treatments, KAE-treated Bsp-/- osteoblasts did not demonstrate as large of an
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Figure 3.4: Decreasing Pparg and Sox9 expression confirms osteoblast
differentiation. Quantitative real-time PCR was performed to assay gene expression of
adipogenic (Pparg) and chrondrogenic (Sox9) markers of maturation. Gene expression
was normalized to B2m. (n=5, *p<0.05)
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Figure 3.5: Adenoviral transduction efficiency of BSP and its mutants in Bsp-/osteoblasts. (A) LacZ staining (blue) of MSC-derived osteoblasts at a multiplicity of
infection of 300. (B) Immunoblot detection of the overexpression of BSP and its mutants
by the MSC-derived osteogenic cells is consistent, while none is detected in the EV
control. (n=3)
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Figure 3.6: Overexpression of BSP and its mutants rescue the impaired
mineralization of the EV-treated Bsp-/- osteoblasts. Alizarin red staining was
performed on tissue cultures and then extracted and assayed spectrophotometrically at
415 nm at weekly intervals beginning at week 2 (A). Quantification of mineralization,
relative to WT at week 2, of the untreated WT and Bsp-/- cells, and EV-treated Bsp-/- cells.
Mineralization from the adenoviral-treated cells quantified at 2 (B), 3 (C), and 4 (D)
weeks. Representative images of each treatment are shown beneath their respective
columns. (n=5, * denotes significance where p<0.05)
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increase in mineralization at week 4 as the other BSP variants relative to the EV controls.
All treatments were then assayed for metabolic activity to ensure they had maintained
normal viability and growth characteristics post-transduction (Figure 3.7). No significant
difference between the treatments was determined, suggesting that the cell number is
unaffected following adenoviral treatment in this system.
3.4.5

Expression of osteoblast markers of maturation are increased by

overexpression of BSP and mutants
In order to determine whether transduction with BSP and its mutants promoted
the differentiation of the osteogenic cultures, we examined the expression of osteoblast
markers of development at day 28 from EV-, BSP-, -28-, and KAE-treated osteoblasts.
Relative to the EV-transduced cells, Alp1 expression increased in the BSP-, -28-, and
KAE-treated cells (Figure 3.8A). Col1a1 expression was increased in the BSP-treated
Bsp-/- cells compared to the EV-treated controls, while the other treatments demonstrated
no change in expression (Figure 3.8B). One major transcription factor, Runx2 was
increased in only the BSP-treated cells relative to cells treated with EV (Figure 3.8C).
The other major transcription factor examined, Sp7, showed significant increases in BSP, -28, and KAE-treated cells relative to the EV-treated controls (Figure 3.8D). Bglap
expression is increased in the BSP- and KAE-treated cultures relative to the EV-treated
control, while expression is unchanged in -28-treated cultures (Figure 3.8E). Dmp1
expression is increased in both the BSP- and KAE-treated osteoblasts while -28-treated
expression remains unchanged, relative to the EV control (Figure 3.8F).
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Figure 3.7: Cell metabolic activity is unchanged upon viral transduction. Curves
from metabolic activity assayed using alamarBlue. Error bars are omitted for clarity. No
significant difference in metabolic activity between treatments was detected. (n=5)
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Figure 3.8: Real-time qPCR of osteogenic marker expression of Bsp-/- osteoblasts
overexpression BSP. Quantitative real-time PCR assaying osteogenic gene expression of
the adenoviral treated Bsp-/- osteoblasts at day 28 in culture. Alp1 (A), Col1a1 (B), Runx2
(C), Sp7 (D), Bglap (E), and Dmp1 (F) were assayed. Adenoviral treatment of Bsp-/osteoblasts included empty-vector (EV), WT BSP (BSP), N-terminal truncated BSP (28), and RGD mutated to KAE (KAE). (n=5, * denotes significantly different from EV
where p<0.05)
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3.5

Discussion
BSP is thought to be an important mediator of mineralization and osteoblast

development [19, 21, 22]. BSP is expressed during the mineralization phase of MC3T3E1 cells [27, 28] and primary osteoblast [15, 16] cultures. The Bsp-/- mouse demonstrates
a phenotype of delayed endochondral ossification (Chapter 2), and osteoblasts derived
from the Bsp-/- mice have been shown to have decreased mineralization potential and
expression of osteogenic markers of development [19]. Similarly, overexpression of BSP
has been shown to increase mineralization and terminal differentiation of osteoblasts in
both MC3T3-E1 cell culture [22] and osteoblasts derived from the CMV-BSP mouse
model [21]. Supplementation of osteogenic cultures with BSP has also been demonstrated
to increase expression of osteoblast-related markers [22, 29]. However, the role of BSP
and its functional motifs and their mechanism of action have yet to be fully characterized
in osteoblasts without interference from endogenous BSP. In this study, we investigated
the phenotype of MSC-derived Bsp-/- osteoblasts, and the effect of overexpressed BSP
and its functional mutants in order to characterize their different functions during
osteoblast development.
The mineralization of the Bsp-/- osteoblasts demonstrated that loss of BSP results
in decreased mineral deposition relative to WT cultures, agreeing with previous work
[19]. There was also a decrease in calcium content at days 3, 6, and 9, suggesting that
loss of BSP delays early mineral deposition, possibly due to BSP’s hydroxyapatite
nucleation activity. The decreased alkaline phosphatase-positive area stained and
metabolic activity in the Bsp-/- osteoblast cultures suggests that cell proliferation is
impaired in the Bsp-/- cultures. Interestingly, Valverde et al also noted a decrease in the
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growth rate of the osteoblasts when BSP was overexpressed [21]. This defect in
proliferation is supported by evidence in the growth plate of decreased chondrocyte
proliferation (Chapter 2). Furthermore, it is postulated that BSP expression occurs at two
times during osteoprogenitor cell development: during the highly proliferative immature
osteoprogenitor phase, and during terminal maturation from preosteoblasts to osteoblasts
[30]. This suggests that low-level BSP expression may promote proliferation, while highlevel expression promotes terminal differentiation.
In our study, the early markers of osteogenic development and transcription factor
expression are unchanged in the Bsp-/- cells compared to the WT controls. The notable
differences are delayed Opn and Bglap expression in the Bsp-/- versus WT cells. This
suggests that the cells have altered differentiation characteristics. While there was no
change in expression of the chondrocyte marker Sox9, there was increased expression of
adipocyte marker Pparg in the Bsp-/- cells. Due to the similar gene expression patterns
and relatively small change in expression, we suspect that the change does not have
physiological relevance. These results, alongside the delayed mineralization phenotype,
suggest that the loss of BSP results in a delay in both osteoblast differentiation and
mineralization in osteogenic cell cultures.
In order to discern which functional regions promote mineralization and/or
differentiation, the effect of adenoviral-mediated overexpression of BSP and its mutants
on the Bsp-/- osteoblasts was examined. The EV-treatment of the Bsp-/- osteoblasts
resulted in some toxicity, as these cells had decreased mineralization compared to the
untreated Bsp-/- cells. Adenoviral transduction with BSP, and its mutants, all rescued the
mineralization to a similar extent at week 3, as compared to the EV-treated control. At
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week 4, BSP, -28, EA, and SA treatments had equivalent effects on promoting
mineralization compared to the EV-treated control, whereas the mineral content mediated
by KAE-transduction while elevated was not to the same level as the other forms of BSP.
If mineralization in these cell cultures was entirely dependent on BSP’s ability to
nucleate and promote mineral formation, then a differing mineral content between the
mutants and wild-type BSP would be expected. The -28 mutant of BSP may not be able
to bind collagen, but it could become trapped within the osteoid maintaining its ability to
promote mineralization and bind cell-surface integrins promoting osteoblast
development. While the recombinant EA mutant had greatly diminished nucleation
potency in the aforementioned cell-free studies [7], this study demonstrated that there
was no decrease in mineralization relative to wild-type BSP in cell culture. This may be
due to the EA mutant still having an overall negative charge that has been demonstrated
to be critical to nucleation of HA [8, 9]. The SA mutant also promoted mineralization
equal to the BSP-treated cells, suggesting that the single phosphorylation is not crucial to
its ability to initiate nucleation in tissue culture. While this version of BSP still has the
collagen-binding domain and poly-E motifs, there is impaired mineralization relative to
wild-type BSP, suggesting that the RGD sequence is likely promoting osteoblastic
differentiation resulting in increased mineralization. BSP’s role in promoting
mineralization in osteoblasts is not solely dependent on any one region and it has multiple
mineralizing motifs to ensure its functionally. These results confirm that BSP is a potent
nucleator of mineralization.
Previous studies have shown that supplementation with recombinant BSP and
overexpression of BSP in osteoblasts promotes osteogenic gene expression in tissue
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cultures [22]. While we observed no change in metabolic activity following adenovirus
treatment, there were differences in osteoblast gene expression characteristics. As
expected, the BSP-treated cells demonstrated increased expression of osteogenic markers
relative to the EV-treated control. When treated with the -28 truncated BSP, the
osteogenic cultures had increased Alp1 and Sp7 expression. Notably, the genes that were
unchanged in the -28-treated cells relative to the EV-treated controls were markers of
terminal differentiation (Bglap and Dmp1). Due to the increased mineralization observed
from this treatment, it is unlikely that the mutant was lost in the medium, suggesting that
there could be a cell signaling sequence different from the RGD motif. Other SIBLING
molecules, of which OPN has been most thoroughly characterized, have been shown to
have multiple cell-surface-binding motifs [31-36]. Interestingly, the KAE mutant
demonstrated increased expression of Alp1, Bglap, and Dmp1. This mutant is unable to
bind the cell-surface integrins through its traditional RGD motif, so the increased gene
expression supports the hypothesis that BSP may have a second signaling motif. These
results demonstrate that wild-type BSP promotes osteogenic gene expression as expected,
and that there is likely a second or more signaling motifs in addition to the RGD integrinbinding motif.
This study investigated the role of BSP during osteoblast differentiation and
mineralization. The loss of BSP resulted in a delay of mineral deposition and maturation
characteristics of osteoblasts. The subsequent treatment of the Bsp-/- osteoblasts with
overexpressed BSP and its mutants resulted in increased mineralization and osteoblast
marker gene expression relative to EV-treated controls. These results suggest that the
functional regions of BSP play different roles in mediating osteoblast maturation and
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mineralization. The RGD signaling motif appeared to be the predominant functional
region of those investigated. However, these data suggest that there is another signaling
motif yet to be characterized at the N-terminus. These data confirm that there are multiple
redundancies within BSP that work cohesively to mediate mineralized tissue
development.
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CHAPTER FOUR

OSTEOPONTIN MEDIATES MINERALIZATION AND NOT
OSTEOGENIC CELL DEVELOPMENT IN VITRO 1

1

This Chapter has been reproduced from:

E. Holm, J.S. Gleberzon, E.S. Sørensen, F. Beier, G.K. Hunter, H.A. Goldberg. 2014.
Osteopontin mediates mineralization and not osteogenic cell development in vitro. (In
revision at Biochemical Journal August, 2014)
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4.1

Chapter Summary
Biomineralization is a complex process in the development of mineralized tissues

such as bone, and pathological calcifications such as atherosclerotic plaques, kidney
stones, gout, and others. Osteopontin (OPN), an anionic phosphoprotein, is expressed in
mineralizing tissues and has previously been demonstrated to be a potent inhibitor of
hydroxyapatite formation. The OPN-deficient mouse (Opn-/-) displays a hypermineralized
bone phenotype starting at 12 weeks post-natally. By isolating and culturing Opn-/- and
wild-type (WT) osteoblasts, we sought to determine the role of OPN and two of its
functional peptides in osteoblast development and mineralization. Opn-/- osteoblasts had
significantly increased mineral deposition relative to their WT counterparts, with no
physiologically relevant change in gene expression of osteogenic markers.
Supplementation with bovine milk OPN (mOPN) lead to a dramatic reduction in mineral
deposition by the Opn-/- osteoblasts. Treatment with OPN peptides corresponding to
phosphorylated OPN220–235 (P3) and non-phosphorylated OPN65–80 (OPAR) also
rescued the hypermineralization phenotype of Opn-/- osteogenic cultures.
Supplementation with mOPN or the OPN-derived peptides did not alter the expression of
terminal osteogenic markers. These data suggest that OPN plays an important role in the
regulation of biomineralization, but does not appear to affect osteoblast cell development
in vitro.
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4.2

Introduction
Biomineralization is an intricately controlled process that comprises osteogenic

cell development as well as the nucleation and growth of hydroxyapatite in calcified
tissues such as bone, imparting them with strength and rigidity. Pathological
dysregulation of mineralization results in a number of disorders such as atherosclerosis
[1], kidney stones [2], and others. A number of mechanisms have been proposed to
account for the regulation of mineralization in vivo, including the involvement of proteins
responsible for mediating osteogenic cell differentiation and the promotion or inhibition
of mineral growth and/or nucleation. One protein implicated in the inhibition of mineral
formation is osteopontin (OPN).
Osteopontin is an anionic phosphoprotein that is expressed in many tissues and
cell types, and is also found in physiological fluids [3]. OPN is a member of the Small
Integrin-Binding Ligand N-linked Glycoprotein (SIBLING) family of proteins [4], which
includes bone sialoprotein (BSP), dentin matrix phosphoprotein (DMP1), and dentin
sialophosphoprotein (DSPP). The genes encoding the SIBLING family of proteins are
located in a syntenic gene locus that has been named the “bone gene cluster” on murine
chromosome 5 [5] and human chromosome 4 [6]. These proteins are intrinsically
disordered, with little or no secondary or tertiary structure [4, 7, 8]. They also contain
RGD (Arginine-Glycine-Aspartate) integrin-binding sequences, highly acidic sequences
that may include poly-aspartate or poly-glutamate sequences, and are highly posttranslationally modified [3]. These post-translational modifications often include
phosphorylation, glycosylation and sulfation.
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The expression patterns of OPN in different tissues are highly complex and
dependent on a variety of regulatory elements. In bone, expression of OPN has been
shown to be linked with the mineralization front of osteoid [9-11]. OPN expression has
also been associated with pathological calcifications, such as atherosclerosis [1] and
kidney stones [12]. The presence of OPN during de novo osteoid deposition and
pathological calcification suggests that OPN may be regulating mineral growth in both
cases. The expression of OPN in osteoblasts is dependent on a variety of regulatory
factors, including: synthetic bisphosphonates [13], inorganic phosphate [14], and 1,25dihydroxyvitamin D3 [13, 15]. When osteoblasts are exposed to cell culture media
containing inorganic pyrophosphate, OPN expression may also be regulated by Ank and
Pc-1 (gene name Enpp1) [16-18]. The expression of OPN is also associated with varying
degrees of post-translational modification in a tissue- and cell-specific manner, recently
reviewed by Ganss and Bansal [3]. OPN’s state of post-translational modification is
implicated in its ability to mediate cell signaling and mineral growth inhibition. Increased
phosphorylation has been shown to be important in promoting osteoclastic activity [19].
Furthermore, native OPN with post-translational modifications is a more potent inhibitor
of HA growth than recombinant OPN lacking these modifications [20].
Mice with the Opn gene ablated (Opn-/-) have been reported to have increased
bone mineral density when assayed using Fourier transform infrared (FTIR) imaging
[21]. This phenotype develops progressively as the animals age [21], suggesting a
dysregulation between mineral deposition and resorption by osteoblasts and osteoclasts,
respectively. Rittling et al. have demonstrated that Opn-/- mice have significantly reduced
osteoclast activity [22], suggesting that the increased mineral density is due to decreased
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resorption. Studies in tissue culture revealed that MSC-derived osteogenic cells from tailsuspended WT mice had decreased mineralization compared to their unsuspended
controls. In contrast, osteogenic cells derived from tail-suspended Opn-/- mice had the
same degree of mineralization as their unsuspended counterparts [23], suggesting OPN
may be involved in the mechanosignal transduction response of osteoblasts. Currently,
there do not appear to be any published studies examining a time course of mineralization
and differentiation of osteoblasts derived from the Opn-/- mice.
Previous work has presented conflicting evidence for OPN’s potential role in
osteogenic cell differentiation [24, 25]. Overexpression of OPN in MC3T3-E1 preosteoblastic cells resulted in a decrease in the expression of mature osteoblast markers in
addition to a decrease in mineral deposition [25]. However, overexpression of OPN in rat
bone marrow cells was shown to enhance the expression of osteoblast markers and
nodule formation [24]. These contradictory results have yet to be resolved. In order to
better understand the role of OPN during bone formation and homeostasis, it is critical to
elucidate its function during osteoblast differentiation and biomineralization.
As previously indicated, OPN has also been shown to be a potent inhibitor of
hydroxyapatite (HA) nucleation and growth in vitro [26, 27]. OPN has been studied
extensively in order to understand the role it plays in regulating crystal growth. Motifs of
OPN shown to inhibit mineralization include the highly acidic poly-aspartate regions [28]
as well as the highly phosphorylated sequences [29]. These crystal-binding regions of
OPN competitively perturb mineral growth by interacting with the positively charged
regions of the crystal surfaces [30]. Bovine milk OPN (mOPN) has been used extensively
in studies of OPN inhibition as it is highly phosphorylated and is readily available in
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large quantities [31]. mOPN has been shown to directly inhibit HA nucleation by binding
crystal faces of HA using its multiple crystal-binding motifs [30, 32].
Due to OPN’s localization within atherosclerotic plaques [33], Giachelli et al
undertook studies using vascular smooth muscle cells (VSMCs) isolated from the Opn-/mouse. These cells were grown under high phosphate conditions to induce calcification,
and were shown to have increased mineral deposition relative to WT controls [34].
Supplementation with exogenous OPN from neonatal rat smooth muscle cell cultures
resulted in a decrease in mineral deposition in the same system [35]. These studies
confirm that OPN is a potent inhibitor of mineral growth and formation in VSMC
cultures.
Of the aforementioned motifs responsible for crystal growth inhibition, we have
characterized OPN sequences with potent inhibitory activity [29]. These include OPN 6580 (SHDHMDDDDDDDDDGD) called OPAR (Osteopontin Poly-Aspartate Region) and
OPN 220-235 (pSHEpSTEQSDAIDpSAEK) termed P3, containing 3 attached
phosphates. The Opn-/- mouse provides an opportunity to test these peptides without
interference from endogenous OPN.
In this study we characterize the phenotype of Opn-/- osteoblasts. We also
determined the inhibitory capacity of mOPN and two functional peptides of OPN, namely
P3 and OPAR. We demonstrate that Opn-/- osteoblast cultures have an increased
mineralization phenotype that is independent of osteoblast differentiation. We also show
that upon treatment with mOPN and OPN derived-peptides, there is a reduction of
mineral deposition with no alteration of the expression characteristics of terminal
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osteoblast markers. These data suggest that the main role of OPN in osteoblasts is to
control mineralization, not cellular differentiation.
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4.3

Materials and methods

4.3.1

Animal protocol
Animal procedures were performed in accordance with guidelines of the Canadian

Council on Animal Care (CCAC) and Animal Care and Veterinary Services (ACVS),
University of Western Ontario protocol number 2008-092. Mice were obtained from The
Jackson Laboratory (JAX), originally documented by Liaw, et al. [36] (JAX Stock
number 004936, Sacramento, USA). Preparation and genotyping of Opn-/- homozygous
mice and WT controls were performed as described by the supplier (JAX). Mice were
maintained on a C57BL/6 background and were fed a standard pelleted mouse diet (2018
Tekland Global 18% protein diet, Harlan Laboratories, USA) and tap water ad libitum.
The Opn-/- and WT mice breed normally and both can be maintained on a homozygous
background.
4.3.2

Milk osteopontin and peptide preparation
Bovine milk OPN, comprising a mixture of both intact and OPN-derived peptides,

was purified as previously described by Sørensen and Petersen [37]. Synthetic peptides
were prepared as previously described [29]. Briefly, peptides (OPAR SHDHMDDDDDDDDDGD, and P3 - pSHEpSTEQSDAIDpSAEK were synthesized
using batch method free amino and carboxyl termini using FMOC chemistry. These were
then purified using HPLC. Purity and protein content were confirmed using electrospray
ionization mass spectrometry and amino acid analysis, respectively.
4.3.3

Cell culture and in vitro assays
Isolation and culture of mesenchymal stromal cells (MSCs) was performed as

previously described with minor modifications [38]. Cells were isolated by flushing the
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femurs of 8-10 week old mice and were allowed to adhere to T-80 flasks (Nunc,
Roskilde, Denmark) for 3 days in Iscove’s Modified Dublecco’s Medium (IMDM) with
10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin (all
reagents from Life Technologies, Burlington, ON, Canada). Cell culture medium was
changed every 48 h. At 70% confluence, cells were passaged into 24- and 96- multi-well
dishes (Nunc) at a density of 1 x 104 cells/cm2. The cells were allowed to proliferate for
three days and were then grown in mineralizing medium containing alpha minimal
essential medium (αMEM) with 10% FBS, 100 U/mL penicillin, 100 µg/mL
streptomycin, and supplemented with 50 µg/mL ascorbate (Sigma-Aldrich, Oakville,
Canada), and 2 mM glycerol-2-phosphate (G2P, Sigma-Aldrich).
To study the effect of OPN on cell development and mineralization, the medium
was supplemented with mOPN at final concentrations of 5, 10, or 20 µg/mL, or with the
OPN peptides, OPAR and P3, at 20 µg/mL. Supplementation of the culture medium with
OPN or its peptides was continued throughout the culture period.
Metabolic activity was measured using alamarBlue® (Life Technologies) reagent.
The main constituent is resazurin which produces a fluorescently active metabolite in
linear proportion to cell number [39, 40]. Fluorescence was measured with excitation and
emission wavelengths of 570 nm and 585 nm, respectively, on a Tecan Safire plate reader
(Tecan Group Ltd, Männedorf, Switzerland). At least three independent experiments
were performed with each done in triplicate.
Mineralization was assayed using alizarin red S dye (Ricca Chemical Company,
Arlington, USA). Cells were fixed in anhydrous ethanol for 10 min at -20°C. These
cultures were then stained with 500 µL of 1% w/v alizarin red S dye and incubated for 10
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min. Unbound stain was removed by washing with distilled water, and then plates
allowed to dry overnight. Images of wells were taken using a LED2500 dissection
microscope with integrated EC3 digital camera (Leica Microsystems GmbH, Concord,
Canada). Dye was then extracted using 1 mL of 0.6 M HCl, 0.7M sodium dodecyl
sulphate (SDS, Sigma-Aldrich) for 1 h while shaking. An aliquot of 200 µL of dye was
transferred to a 96-well plate and absorbance measured at 415 nm on an iMark plate
reader (BioRad, Mississauga, Canada). At least three independent experiments were
performed with each done in triplicate.
4.3.4

Real-time quantitative PCR
Total RNA was isolated from cells using TRIzol (Life Technologies) according to

manufacturer’s guidelines. PCR reactions were performed using One-step Master mix
(4309169, Life Technologies) on a 7900 HT system (Life Technologies) according to
manufacturer guidelines. Gene expression assays of Alp1, Col1a1, Osterix, Runx2, Sp7,
Osteocalcin, Opn, Dmp1, and Ibsp were performed using Taqman probes (Life
Technologies). Beta-2-microglobulin (B2M) was used as a reference gene for
normalization of expression and relative quantification. These genes and their protein
codes are shown in Table 4.1.
4.3.5

Statistical analyses
Statistical analysis was performed using a two-way ANOVA for time-course

studies, and one-way ANOVA for single time-point experiments. Both were analyzed
with post-hoc Tukey’s test using GraphPad Prism v4.00.
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Table 4.1: Gene names associated with their protein names and primer codes used
for real-time qPCR.
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4.4

Results

4.4.1

Characterization of Opn-/- osteoblasts
In order to study the effect of OPN on extracellular matrix mineralization, we first

assayed the ability of Opn-/- osteoblasts to mineralize in tissue culture. Staining with
alizarin red S showed a linear increase in mineralization in the WT osteogenic cultures
throughout the time course. The Opn-/- cells demonstrated a similar linear increase in
mineralization over time, however there is two-fold greater mineral content relative to
WT cells at each time point (Figure 4.1A & B). There was no apparent difference in
metabolic activity between the Opn-/- and WT cultures, suggesting that the differences in
mineralization are not due to differences in cell number (Figure 4.1C).
Using quantitative real-time PCR, we observed no deviation from WT expression
patterns in a number of osteogenic genes from the Opn-/- cells, including: Ank, Alp1,
Bglap, and Dmp1 (Figure 4.2). Transcription factors Runx2 and Sp7 (data not shown)
were also unchanged. Other osteogenic genes showed some differences. Col1a1
expression was reduced by half at day 7, and by 40% at day 14, in the Opn-/- osteoblasts
relative to the WT cells. Expression of Ibsp at day 14 was increased by 100% in the Opn/-

cells compared with the WT cultures. The expression of Enpp1 was also increased by

60% in the Opn-/- osteogenic cultures at day 28 versus the WT cells. Other than these
exceptions, the expression characteristics are indistinguishable between the WT and Opn/-

cells. The overall similarity in expression of multiple genes throughout the time course

suggests that OPN does not play a critical role in the maturation of osteoblasts.
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Figure 4.1: Biomineralization is increased in the Opn-/- osteoblasts. (A) Quantification
of alizarin red dye extracted from Opn-/- (dotted line) and WT (solid line) cultures at
weekly time points. (B) Representative images of the alizarin red-dyed experimental
wells. (C) Metabolic activity assay of Opn-/- and WT cultures at weekly time points. *
denotes significance where p<0.05, n=4.
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Figure 4.2: Analyses of osteogenic marker expression in Opn-/- osteoblasts show few
changes in developmental expression characteristics using real-time quantitative
PCR. Quantitative real-time PCR examining markers of osteoblastic differentiation taken
at weekly time points. The expression of all genes is normalized to B2m. * denotes
significance where p<0.05, n=4.
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4.4.2 Treatment with mOPN
The enhanced mineralization observed in the Opn-/- osteoblasts, in the absence of
any large changes in cell metabolic activity or expression of differentiation markers,
suggests that OPN functions to primarily inhibit mineral deposition and/or growth.
Therefore, we sought to determine whether supplementing the osteoblast cultures with
mOPN could attenuate the increased mineralization phenotype. Upon treatment with
mOPN, the Opn-/- cultures displayed a significant inhibition of mineralization (Figure
4.3A). The amount of mineral detected in the mOPN-treated Opn-/- osteoblast cultures
following treatment with 5 µg/ml of mOPN was reduced to 10% of the amount in
untreated Opn-/- cell cultures. Higher concentrations of mOPN, 10 and 20 µg/ml, resulted
in even lower (~2.5%) mineral deposition. We observed no change in metabolic activity
(Figure 4.3C), nor were there any changes in terminal-marker expression (Figure 4.4)
upon treatment with mOPN. This suggests that mOPN treatment inhibits mineralization
independent of mediating cellular responses with the osteoblasts in our system.
4.4.3 Treatment with OPN peptides
OPN has multiple sequences within the molecule that have been shown to be
potent inhibitors of mineral formation by in vitro and in silico studies [29]. To determine
whether some of these peptides affect cell-mediated mineralization, osteoblastic cells
from the Opn-/- mouse were cultured in the presence of 20 µg/mL OPAR and P3. As
before, there was increased mineral deposition in the Opn-/- osteogenic cell cultures as
compared with the WT cell cultures. The addition of OPAR and P3 reduced the
mineralization to half of that of the untreated Opn-/- cells. These peptides did not alter the
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metabolic activity characteristics (Figure 4.5B), nor did they change Ibsp or Bglap
expression (Figure 4.6).
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Figure 4.3: Supplementation with mOPN attenuates Opn-/- osteoblast
biomineralization. (A) Quantification of mineralization of cultures at 28 days postinduction. Mineralization was assayed by measuring extracted alizarin red at A415 and
normalizing to WT levels. (B) Representative images of the osteoblast cultures stained
with alizarin red. (C) Metabolic activity of the osteoblast cultures at day 28. * denotes
significance where p<0.05, n=4.
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Figure 4.4: Treatment with mOPN does not change expression of terminal
osteogenic markers of differentiation of Opn-/- osteoblasts. Real-time qPCR was used
to measure expression of Bglap and Ibsp in the untreated and the mOPN-treated
osteoblast cultures at 28 days post-induction. The x-axis represents the amount of mOPN
supplemented in µg/mL. * denotes significance where p<0.05, n=4.
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Figure 4.5: Opn-/- osteoblast biomineralization is attenuated upon supplementation
with P3 and OPAR. (A) Quantification of mineralization of cultures at day 28.
Mineralization was assayed by measuring extracted alizarin red at A415 nm and
normalizing to WT levels. (B) Representative images of alizarin red stain of cells treated
with OPN peptides. (C) Metabolic activity of the cell cultures at day 28. * denotes
significance where p<0.05, n=3.
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Figure 4.6: Supplementation of cultures with OPN peptides does not change
maturation characteristics of Opn-/- osteoblastic cells. Real-time qPCR of Bglap and
Ibsp expression of the cultures treated with 20 µg/ml OPAR and P3 at day 28. * denotes
significance where p<0.05, n=3.
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4.5 Discussion
The Opn-/- mice were originally characterized to have no significant
phenotype [22]. As techniques became more sensitive, and as the mice were challenged,
phenotypic differences became apparent. As adults, the Opn-/- mice show increased
mineralization of their trabecular bone [21]. This increase in site-specific mineral density
was suggested to be due to decreased osteoclast activity [21]. However, other studies
suggest that OPN plays a role in promoting osteogenic development. For example, it was
recently proposed that OPN interaction with cell-surface integrins promotes osteogenesis
of MSCs by virtue of inhibiting adipogenesis [41]. It also has been shown that loss of
OPN results in aberrations of signaling pathways in osteogenic cells mediated by, for
example, parathyroid hormone (PTH) [42] and alkaline phosphatase (Akp2) [17]. These
findings suggest that OPN is a regulator of bone homeostasis. In order to better
understand the role of OPN in osteoblast-mediated biomineralization, we characterized a
time course of gene expression and mineralization in Opn-/- osteoblasts and confirmed
our findings by the addition of exogenous OPN and OPN-derived peptides.
Our studies demonstrate that Opn-/- osteoblasts mediated significantly more
mineral deposition in vitro, while the apparent cell number, based on assessment of
metabolic activity, and expression of markers for differentiated osteoblasts remained
essentially unchanged with a couple of exceptions, as discussed below. This suggests that
the increase in mineralization is likely due to growth of the mineral component and not
an increase in cell numbers nor enhanced differentiation of osteogenic cells. The potential
for OPN to alter the cell-maturation characteristics of osteoblasts is controversial. In a
variety of cell types, including cancer cells, OPN’s interaction with cell-surface integrins
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or CD44 mediates cell signaling leading to specific responses [3, 43]. As such, OPN is
predicted to play a role in promoting osteoblast signaling [44, 45], but, as discussed
previously, OPN has been shown to both promote [24] and inhibit [25] osteoblast
differentiation. The contradictory results of these studies could be due to a multitude of
factors, such as different cell types (primary rat osteoblasts versus MC3T3-E1 preosteoblastic cells) or method of OPN gene delivery (adenovirus versus transfection). The
method of OPN delivery is important as OPN may be capable of initiating cell-signaling
through an intracellular mechanism [46, 47].
In our study, the time course of osteoblast marker expression showed no major
overall changes in expression patterns other than Col1a1. A decrease in Col1a1
expression may be interpreted as fewer sites for early mineral formation and thus lower
mineral deposition. Despite this, we still observed increased mineralization in the Opn-/cells in our study. It was of interest that the expression of Ank and Enpp1 in the Opn-/cells, except Enpp1 at day 28, did not show a difference when compared to WT cells.
These genes encode transmembrane proteins that are thought to regulate
biomineralization: Ank is responsible for the transport of pyrophosphate, a potent
inhibitor of mineral formation, out of the cell [48, 49]; Pc-1 (gene name Enpp1) is an
enzyme that degrades nucleoside triphosphates to produce pyrophosphate [50-52]. The
observed increase in Enpp1 at day 28 may have been a response to the increased
mineralization in these cultures, similar to the expression of Enpp1 of mineralizing
cementoblasts in vitro [53]. In contrast to our studies, previous work has demonstrated
that the osteoblasts derived from the Opn-/- mouse have enhanced expression of both Ank
and Enpp1 [17], proposed to compensate for the loss of OPN’s mineral inhibitory
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activity. The discrepancies between expression of Ank and Enpp1 in our study and that of
Millan’s group [17] may be due to differences in experimental procedures. Our system
used stromal-derived in contrast to calvarial-derived osteogenic cells used by Harmey et
al. [17], thus differing in both cell lineage and stage of development when isolated. The
mice from which the cells were isolated came from two independently produced Opn-/mouse strains; ours from Liaw et al [36], and the Millan group from Rittling et al [22].
We also used 2 mM G2P, a more physiologically relevant concentration [54, 55],
compared to 5 mM G2P used by Harmey et al [17]. It is of relevance that higher G2P
concentration in the culture medium has been shown to increase inorganic phosphate,
which can result in non-specific calcification [55, 56] and promotion of osteoblast
differentiation [57-59]. In our study the loss of OPN does not appear to alter the
expression of the major osteogenic markers.
To determine whether the hypermineralization phenotype of the Opn-/- cells could
be rescued, we treated the cells with mOPN. The addition of mOPN resulted in levels of
mineralization well below that of untreated Opn-/- osteogenic cell cultures. The
unchanged levels of Ibsp and Bglap expression suggest that mOPN treatment resulted in
no change in osteoblast development. Furthermore, we observed no change in metabolic
activity upon treatment with mOPN, suggesting that changes in mineralization were not a
reflection of changes in cell number.
Previous work delineating the role of OPN in VSMCs has demonstrated a similar
attenuation of mineralization upon addition of OPN [35]. Calcification in the VSMCs
was induced using mineralizing medium (including 10 mM G2P), which was
supplemented with 0.5-5 µg/mL OPN [35]. This treatment resulted in a decrease in
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mineralization similar to that shown in our study on osteogenic cells. This confirms that
in mineralizing cell culture systems OPN is a potent inhibitor of mineralization.
To further our understanding of OPN’s mode of mineral inhibition, we
investigated OPN-peptides that were previously shown to inhibit the growth of
hydroxyapatite [29] and calcium oxalate monohydrate crystals [60]. Upon
supplementation with OPAR and the phosphorylated P3 peptide, mineral deposition in
Opn-/- osteoblast cultures was reduced relative to the untreated Opn-/- cells, to a level
comparable to the WT osteoblast cultures. Furthermore, the expression of mature
osteoblast markers was unchanged by the treatments. Thus, the two OPN-derived
peptides, P3 and OPAR, were capable of rescuing the hypermineralization phenotype of
the Opn-/- osteoblast cultures, with no change in terminal differentiation of the Opn-/cells.
In this study we demonstrated that Opn-/- osteoblasts demonstrate greater
biomineralization than WT cells in vitro and that the hypermineralization is rescued by
the addition of mOPN and OPN-peptides. Since there was little change in osteoblast
marker expression, we can conclude that OPN mediates its inhibitory effects in the
extracellular matrix on the nucleation and growth of mineral crystals. Lastly, the rescue
of the hypermineralization phenotype by the inhibitory OPN-derived peptides, without
any apparent effect on osteogenic cell differentiation, provides insight into a possible
avenue for the development of clinical targets to prevent pathological calcifications.
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CHAPTER FIVE

GENERAL DISCUSSION AND CONCLUSIONS
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5.1

Thesis summary
The aim of this thesis was to characterize the role of the SIBLING proteins BSP

and OPN in the processes of endochondral ossification and biomineralization, and
provide evidence to understand the resultant phenotypes in mice when these proteins are
lost. The mechanisms by which mineral crystal growth is initiated and regulated in vivo
remain unclear. BSP and OPN have been demonstrated to be potent regulators of mineral
growth in vitro. In this thesis, BSP and OPN were shown to be contributors to the
initiation and inhibition of mineralization in cell-based systems. BSP was proposed to be
a promoter of osteogenic cell differentiation and chondrocyte cell cycle progression. The
characterization of the roles of these proteins, particularly during development, facilitates
the understanding of mineralized tissue formation and their roles in normal growth and
development.
Endochondral ossification requires complex regulatory mechanisms that mediate
the production of ECM, cell development, and biomineralization. When these processes
are not perfectly balanced, they result in a variety of skeletal dysplasias in bone [1, 2],
and odontogenic defects in oral biology [3-5]. The characterization of the roles of
SIBLING proteins during the development of these tissues will help provide insight for
the development of novel therapeutics for treatment of these pathologies.
The loss of BSP in endochondral bone development resulted in a delay of primary
ossification in the mouse model. This delay during ossification suggested that BSP is
important for both the differentiation of osteoblasts and the resulting mineralization of
bone. The data from the studies on the Bsp-/- osteoblasts support these findings of delayed
mineralization and differentiation characteristics, as in vitro mineralization was also
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delayed. This delay was rescued upon re-introducing BSP using an overexpression
system. These data suggest that BSP is both a nucleator of mineralization and a promoter
of osteoblast development and/or recruitment during endochondral ossification. The loss
of OPN in osteoblasts resulted in increased mineralization, while there was no overall
change to their gene expression characteristics. Thus, OPN is directly involved in mineral
growth inhibition, although it does not appear to be involved in osteoblast differentiation.
Overall, these data confirm the importance of BSP and OPN during mineralization in
vivo, and provide understanding into the developmental roles of SIBLING proteins
during development.
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5.2

Contributions and significance of findings

5.2.1

BSP and endochondral ossification
Prior to undertaking this study, BSP was shown to be a positive regulator of

mineralization and osteoblast differentiation [6]. In this thesis the loss of BSP in mice
was demonstrated to result in decreased neonatal bone length and mineralization, in
agreement with findings by Malaval et al. in 4 month old Bsp-/- animals [7]. BSP was
also shown to be a promoter of endochondral ossification and cell cycle progression of
growth plate chondrocytes. The impaired cell cycle progression of chondrocytes within
the growth plate suggests that this contributes to the decrease in bone length of the Bsp-/mouse. Primary ossification was delayed during early development; neonatal Bsp-/- mice
demonstrated decreased mineralization and expression of osteogenic markers. These
results suggest that ossification is delayed leading to the phenotypes observed in the Bsp-/mice.
The Bsp-/- mouse has impaired repair mechanisms following injury, specifically
delayed mineralization of newly formed bone in a cortical gap model [8, 9]. The
mineralization defects observed during development may be applicable to the mechanism
by which bone repair is delayed. The study presented in this thesis suggests that
osteogenic differentiation and/or recruitment is delayed which could lead to impaired
callus formation following injury, and delayed mineralization of the repaired tissues. This
suggests that BSP is an important molecule directing bone repair, although during
development its loss may be compensated for by other SIBLING group members, or
other proteins with similar functionalities.
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The loss of BSP resulted in delayed development and shortened bones, however
as the mice age their bone lengths become normalized relative to their controls [7].
Interestingly, the loss of BSP also results in a deficiency of acellular cementum of teeth
in adult mice [10]. This suggests that BSP is an important regulator of mineralized tissue
formation, but in bone the loss of BSP is compensated for by another mechanism that is
not recapitulated in acellular cementum. Thus, this study demonstrates that BSP has a
variety of functions in the skeleton, which differ both temporally and spatially.
5.2.2

SIBLING proteins regulate osteogenic mineralization
In this thesis the SIBLING proteins BSP and OPN were shown to be capable of

directing biomineralization and growth. BSP is known to be a potent nucleator of
mineralization in both cell-free [11] and osteoblast studies [12, 13]. BSP-mediated
mineralization is potentiated by binding to collagen [14, 15], and its efficacy as a
nucleator is dependent on the contiguous glutamate sequences [16], and its
phosphorylation status [16, 17]. The RGD integrin-binding sequence has also been shown
to promote osteoblast differentiation, resulting in increased mineralization [13]. However,
characterization of these functional motifs has not been conducted in a cell-based system.
In order to ultimately study the role of the functional motifs of BSP, the untreated
Bsp-/- osteogenic cultures required characterization. Therein Bsp-/- osteoblasts were
demonstrated to have delayed mineralization and differentiation (Chapter 3).
Additionally, the osteogenic cultures had decreased metabolic activity, suggesting that
cell proliferation is reduced. The delayed mineralization and differentiation is similar to
the delayed endochondral ossification in vivo in the Bsp-/- mouse (Chapter 2). This lead to
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the conclusion that the loss of BSP results in delayed osteogenic development and
differentiation that contributes to the phenotype of Bsp-/- mice.
Overexpression of BSP in the Bsp-/- osteogenic cultures resulted in promoting
mineralization and osteogenic gene expression compared to the EV control. These results
agreed with previous work where overexpression of BSP in wild-type osteogenic cells
promotes mineralization and osteoblastic differentiation [13]. Similarly, siRNA
knockdown of Bsp expression resulted in decreased mineralization and decreased gene
expression of osteoblast markers Runx2, Sp7, and Bglap [13]. These previous studies
implicated the RGD motif as a critical promoter of osteoblast differentiation, thereby
promoting mineralization. Our studies investigating the overexpression of BSP in Bsp-/osteogenic cultures demonstrated that loss of any of the functional-domains of BSP was
insufficient to completely ablate its mineralization and signaling capabilities (Chapter 3).
Even the RGD to KAE BSP mutant retained similar mineralization capabilities at week 4
as wild-type BSP. This is contrary to previous findings suggesting that the RGD sequence
is crucial to the functionality of BSP. These results also suggested that BSP may contain
a secondary osteoblast signaling motif that is not yet identified. These findings support
previous work, both cell- and cell-free-based, that have shown BSP to be a potent
promoter of biomineralization.
Similar to BSP, OPN has been examined in cell-free studies and determined that it
is a potent inhibitor of mineralization [18-20]. OPN is also predicted to be a promoter of
cell differentiation due to RGD-integrin interactions [21, 22], although its signaling
capabilities in osteoblasts is still contentious. Conflicting studies suggested that OPN
either promotes [23] or inhibits [24] differentiation, resulting in increased or decreased
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mineralization. The loss of OPN was demonstrated to result in increased mineralization
in osteogenic cultures, while having no overall change in gene expression characteristics
(Chapter 4). Furthermore, supplementation of the cultures with exogenous mOPN
resulted in no change in terminal marker expression or metabolic activity. These results
contribute evidence to suggest that the role of OPN in osteogenic cell cultures is strictly
the modulation of mineralization.
These studies present data that contribute to the understanding of SIBLING
protein function in skeletal development and homeostasis. The Bsp-/- mouse demonstrates
delayed ossification during endochondral bone development that could be caused, in part,
by delayed in osteoblast differentiation. Similarly, the Opn-/- mouse has increased bone
density that could partly be due to mineral growth being less encumbered. The results
from these studies provide insight into the roles of these proteins regulating matrix
mineralization in vivo.
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5.3

Limitations of research and future directions

5.3.1

Limitations of the Bsp-/- mouse model
This thesis has presented novel findings regarding the role of BSP in

endochondral ossification. While loss of BSP during development appears to directly
result in a delay of mineralization, the mechanism by which this delay occurs has yet to
be elucidated. It is still unclear whether the delay is due to impaired osteogenic cell
differentiation, impaired recruitment of these cells, or a combination of the two. The
mechanism of cell cycle delay of growth plate chondrocytes is also not entirely clear.
Delineation of these mechanisms would provide a more complete understanding of the
function of BSP in the development and repair of endochondral bone.
In order to investigate the underlying cause of delayed endochondral ossification,
mechanistic characterization of the developing tibiae must be performed. This can be
accomplished by performing microdissections to isolate and characterize the resting,
proliferating, and hypertrophic zones of developing long bones individually at E15.5
[25]. This analysis will specifically identify the genes that may be altered upon the loss of
BSP, and identify which developmental stage is directly affected by the loss of function.
Specifically, the use of next-generation RNA sequencing will provide substantially more
data regarding the expression changes upon loss of BSP. This could also be applied to
investigate the phenotype of OPN loss during development. The complete
characterization of the expression patterns of these cells during endochondral ossification
would provide evidence as to which pathways are impaired, and whether a compensatory
mechanism is in place.
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Another shortcoming of the mouse model is that the role of BSP is elucidated
only in the context of a whole-body loss of function. This makes separating the primary
and secondary effects of BSP loss difficult to isolate. It is impossible to determine if a
growth plate defect is due to direct loss of function within the chondrocytes, or due to
loss of expression of BSP from the osteoblasts or other cell types. A conditional mutant
where the Bsp gene can be deleted in either cell type specifically will more readily enable
characterization of the specific roles of BSP. A conditional mutant would also provide
interesting evidence to examine the mechanism of the loss of cementum in the Bsp-/mouse. These mutants can be achieved by crossing either a cartilage- [26] or bone- [27]
specific Cre recombinase with a floxed allele of Bsp.
A number of the SIBLING group of proteins are closely related in expression and
function during mineralized tissue development. The limited phenotypes observed in all
loss of function mice, including Bsp-/- and Opn/- mice, are likely due to a compensatory
mechanism provided by the related proteins, or those related in function. Thus, the
deletion of multiple genes in the same model would characterize the potential interplay
between these proteins. Insight into which genes would be viable targets would include
those that were identified in the RNA sequencing experiment, described above. For
example, the Opn-/- mouse has been demonstrated to have a mild phenotype, but when
matrix gla protein (MGP) is ablated alongside OPN, the phenotype of atherosclerosis is
exacerbated dramatically [28]. Similarly, when the hypomineralized Akp2 ablated mouse
is crossed with the Opn-/- mouse, the mineralization phenotype is partially corrected [29].
This suggests that other proteins with similar functionalities may be performing
compensatory mechanisms in the Opn-/- mouse. Similarly, the deletion of either Bsp [7,
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10] or Dmp1 [30, 31] results in impaired development of endochondral bone and teeth.
The deletion of both genes may exacerbate the phenotypes resulting in improperly
formed bones. Due to the SIBLING genes all being within a syntentic gene locus, the
deletion of multiple genes within the group is nearly impossible through cross-breeding.
Therefore to study the loss of function of any two genes from the SIBLING group would
require homologous recombination and insertion into a blastocyst from one of the
currently derived models. Nevertheless, this would present an approach to understand the
interplay between the proteins involved in mineralization and ossification.
5.3.2

Osteogenic cell culture models
In this thesis, osteoblast cultures were used to further the understanding of

SIBLING proteins in the regulation of mineral formation and growth in a cell-based
system. The studies of these cells in culture can be extended to characterize the
phenotypes of the loss of function in mice. These cells were isolated from bone
mesenchyme of 8 to 10 week old mice and were grown in a monolayer culture system.
The cells proliferate and are grown at high-density, simulating physiological levels of cell
to cell contact to replicate the conditions in vivo [32]. These mesenchymal-derived cells
contain pluripotent progenitors that are capable of differentiating into cartilage, bone,
adipose, and muscle [33]. In order to induce osteogenic differentiation the cultures were
treated with ascorbate and glycerol-2-phosphate. While these cells are removed from the
microenvironment of neighbouring tissues, it permits direct study of the phenotype upon
loss of the Bsp or Opn gene.
The gene expression patterns following isolation demonstrated that the cultures
had expected patterns of osteogenic marker expression, and decreases in both chondro-
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and adipogenic marker expression. This demonstrated that the isolated cells differentiated
along the osteoblast lineage, but it is impossible to confirm that the cultures were a
homogenous population of osteoblasts. It is possible there were other cell types within the
isolation, such as fibroblasts, adipocytes, and chondrocytes. Additionally, these cells are
very sensitive to confluence and subculturing. If they are grown to a high confluence, or
more than one subculture prior to induction, the cells lose their osteogenic phenotype and
tend to become senescent (unpublished data). This can result in increased variability
within the system if the cells are not handled identically in culture.
While this cell culture system is a more physiologically relevant model than the
cell-free studies, it does have its own limitations in regards to data interpretation and how
it applies in vivo. The mechanism of mineralization in vivo involves many variables; there
is interaction with other cell types, different ECMs, and a multitude of signaling
molecules including those from mechanical stress and the endocrine system. This is
supported by the osteogenic cultures demonstrating large differences in mineralization
upon loss of BSP and OPN compared to WT cultures in vitro, while the phenotype of the
mouse is not severe. This is likely due to any number of the other aforementioned
compensatory factors within a living animal.
The overexpression of BSP using adenovirus in osteogenic cultures permits
expression containing post-translational modifications. The post-translational
modification of this overexpressed BSP is predicted to be equivalent to that which is
secreted by osteoblasts in vivo. The limitations of adenoviral transduction in this system
are mainly due to the toxicity. The very high MOI required to transduce a sufficient
number of cells resulted in impaired mineralization upon EV treatment. There also
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appeared to be a trend downwards in the metabolic activity upon treatment with the
adenovirus, which may have been rescued by BSP overexpression. WT cells would need
to be treated with adenovirus in addition to the Bsp-/- osteogenic cultures to distinguish
between the effects of the virus and BSP. Overexpression of proteins may also result in a
number of differences in cell metabolism and differentiation. This resulting
overexpression of BSP occurs at an earlier time and at a higher level than during typical
osteoblast differentiation [34]. This may result in BSP-mediated cell signaling earlier
than what would happen in normal differentiation, subsequently resulting in premature
terminal differentiation.
In order to address many of the shortcomings of an adenoviral system, future
experiments should be performed using a lentivirus to mediate gene transduction.
Lentiviruses will more readily transduce primary mesenchymal cells than an adenoviral
vector [35, 36]. This system will also incorporate the gene of interest directly into the
genome, preventing dilution due to cell division which occurs in cells that are transduced
with adenovirus. The genes will also be controlled under a different promoter than the
CMV promoter. The CMV promoter, used in the adenovirus system, constitutively
expresses a very high level of protein that may alter the availability of cellular machinery
for production of the normal proteins and express the protein(s) at non-physiological
levels. In contrast, treatment with a lentiviral vector normally results in a consistent lower
level of expression. These studies should address many of the limitations from the
adenovirus vectors used in this study and also provide an opportunity to perform stable
integration and expression in vivo, such as the experiment proposed below.
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The Bsp-/- mouse demonstrates a loss of acellular cementum, leading to an acute
periodontal tissue phenotype that we can attempt to rescue. Due to this phenotype,
functional motif mutants of BSP can be expressed in vivo in order determine their
importance during acellular cementum formation. A similar phenotype [37, 38] and
rescue has been performed with the Akp2-/- mouse [39, 40]. The investigators attached a
deca-aspartate sequence of amino acids to promote the binding of TNAP to mineralized
tissues such as acellular cementum. Since BSP contains a strong negative charge, the
rescue by intraperitoneal injection of neonates should permit it to bind to the mineralized
tissues in a similar manner. This system should result in a rescue of the phenotype of loss
of acellular cementum, which will be confirmed by histological assays and micro
computed tomography. This will provide an in vivo model that BSP and its functional
motifs could be studied.
In the study characterizing the role of OPN (Chapter 4), the cultures were
supplemented with exogenous, fully phosphorylated bovine milk OPN (28
phosphorylations). This amount of phosphorylation differs from normal OPN expressed
by osteoblasts, which is approximately 30% phosphorylated (10-11 phosphorylations)
[41]. Phosphorylation of OPN has been demonstrated to modulate its signaling
capabilities [42]. In order to understand whether OPN is a signaling molecule in
osteoblasts, additional studies would need to be performed. Supplementation of the
osteoblast cultures with native rat OPN isolated from bone would provide a more
physiological post-translationally modified protein as a control. Determining whether
supplementation would result in inhibition similar to the milk OPN model would bolster
evidence for OPN as an inhibitor of mineralization, and not a promoter of cell signaling,
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in a culture-based system. To control for the phosphorylated native OPN,
nonphosphorylated recombinant rat OPN may be used. Using recombinant OPN with a
mutation of the integrin-binding RGD motif to the KAE would also delineate how OPN
inhibits mineralization by eliminating the confounding effects of integrin-mediated
signaling. These experiments would provide conclusive results to whether OPN promotes
or inhibits osteoblast differentiation. There is also data to suggest that intracellular OPN
is a promoter of differentiation [43, 44]. In order to confirm whether this is a
characteristic of OPN in osteoblasts, lentiviral transduction of wild-type and functional
domain mutants into Opn-/- mice could provide insight similar to that proposed for BSP.
The future experiments characterizing the roles of BSP and OPN in osteoblasts
and in mice would provide valuable insight into their roles during development. This will
improve the understanding into the mechanisms of how mineralized tissues are calcified
and how the cells that regulate their development function. The characterization of
normal development will further our understanding of skeletal disease, thereby providing
insight into the development of novel therapeutics for the treatment of pathological
mineralization.
5.3.3 Future directions investigating BSP in osteoarthritis
Recently BSP has been demonstrated to be highly expressed in pathological
osteoarthritis (OA) in humans [45]. During OA, the articular cartilage of joints undergoes
a number of changes that ultimately result in its degradation. The development of OA has
demonstrated that articular chondrocytes begin to undergo differentiation that resembles
chondrocyte hypertrophy [46]. As mentioned previously, hypertrophic chondrocytes
express BSP, MMPs, and vascular growth factors. This induces the mineralization of the
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articular cartilage, degradation of the tissue by MMPs, and promotes vascular invasion of
a normally avascular tissue (reviewed in [47]). As BSP is a promoter of matrix
mineralization and hallmark of hypertrophic chondrocytes, determining its role in OA
could provide insight into the mechanism of pathological development.
A number of methods designed to study OA in mice have been developed
(reviewed in [48]). These surgeries result in the destabilization of the knee joint that
induces OA. One popular method in mice involves destabilization of the medial meniscus
by medial meniscotibial ligament transection [49, 50]. Following surgery, OA develops
between four to ten weeks. As BSP has been implicated to be highly expressed in OA
[45, 51], examination of this model in the Bsp-/- mouse presents an opportunity to
investigate OA without endogenous BSP expression. Histological characterization of the
pathogenesis of OA would demonstrate the function of BSP during articular cartilage
degradation. The correlation with BSP and OA suggests that the loss of BSP will provide
a protective effect with less severe OA being present. Characterization of the
pathogenesis could implicate BSP as an instigator of OA.
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5.4

Conclusions
These studies have demonstrated that BSP and OPN are important regulators in

the formation and growth of biomineral within the skeleton. This thesis has identified
specific roles for BSP in primary ossification during endochondral bone development.
This provides insight into bone biology and normal development, with a focus on proper
regulation of mineralization. The loss of BSP in vitro also recapitulated the phenotype of
the BSP loss of function mouse. This thesis also identifies OPN as a potent regulator of
mineralization, which does not appear to function through signalling pathways in
osteogenic cell development. The characterization of these proteins during mineralization
provides evidence to suggest these could be valuable clinical targets for the prevention or
treatment of diseases associated with pathological calcifications.
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Appendix A: Statement of Permission for the Use of Animals for Experimental Research.
All animal experimentation was performed in compliance with the animal use protocol
2008-092. This protocol is held by Dr. Harvey Goldberg, a principal investigator at the Schulich
School of Medicine and Dentistry and the department of Biochemistry at the University of
Western Ontario in London, Ontario, Canada.

2008-092::5:
AUP Number: 2008-092
AUP Title: Functional Characterization of Bone Sialoprotein Using the BSP-null Mouse
Yearly Renewal Date: 11/01/2013
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2008-092 has been
approved, and will be approved for one year following the above review date.
1. This AUP number must be indicated when ordering animals for this
project.
2. Animals for other projects may not be ordered under this AUP number.
3. Purchases of animals other than through this system must be cleared
through the ACVS office.
Health certificates will be required.
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in
this protocol, are familiar with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated
safety components (biosafety, radiation safety, general laboratory safety) comply with
institutional safety standards and have received all necessary approvals. Please consult
directly with your institutional safety officers.
Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee
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